

# Do Medical Treatments Work for Work? Evidence from Breast Cancer Patients<sup>\*</sup>

N. Meltem Daysal                                  William N. Evans  
University of Copenhagen,                         University of Notre Dame,  
CEBI, CESifo, and IZA                              NBER, and J-PAL  
  
Mikkel Hasse Pedersen                              Mircea Trandafir  
EY Denmark    Rockwool Foundation and IZA

December 2024

## Abstract

We investigate the effects of radiation therapy on the mortality and economic outcomes of breast cancer patients. We implement a 2SLS strategy within a difference-in-differences framework exploiting variation in treatment stemming from a medical guideline change in Denmark. We reproduce the results from an RCT showing the lifesaving benefits of radiotherapy. We then show radiation therapy also has economic returns: ten years after diagnosis, treatment increases employment by 37% and earnings by 45%. Previous work has documented a substantial employment drop after a breast cancer diagnosis. Our results imply that radiation therapy can reduce this effect by 70%.

Keywords: breast cancer, medical treatments, employment, mortality

JEL Classifications: I10, I14, I18, J20

---

\*Daysal: Department of Economics, University of Copenhagen, CEBI, CESifo, IZA (email: [meltem.daysal@econ.ku.dk](mailto:meltem.daysal@econ.ku.dk)); Evans: Department of Economics, University of Notre Dame, NBER, J-PAL (email: [wevans1@nd.edu](mailto:wevans1@nd.edu)); Pedersen: EY Denmark (email: [mikkelpedersen@mail.com](mailto:mikkelpedersen@mail.com)) Trandafir: Rockwool Foundation Research Unit and IZA (email: [mt@rff.dk](mailto:mt@rff.dk)). We are grateful for comments provided by Marianne Bitler, James Fenske, Julian Vedeler Johnsen, Jon Kolstad, Jon Skinner and participants at NHH PhD Course on “New Frontiers in Human Capital”, 2016 Workshop of the Danish Graduate Programme in Economics, HEDG Mini Workshop for Young Scholars, KORA Public Policies, Health and Health Behaviours, 4th SDU Workshop on Applied Microeconomics, 2017 IHEA Meetings, SDU Workshop on Medical Interventions and Socio-Economic Outcomes, PROMETEO workshop, 2021 EALE meetings, and seminar participants at Bristol, Essex, NHH, SOFI, and VATT. Daysal gratefully acknowledges financial support from the Danish Council for Independent Research (grant number 4182-00214). The authors bear sole responsibility for the content of this paper.

# 1 Introduction

Following the seminal work of Grossman (1972) on the theory of health capital, an extensive body of research in economics suggests that healthier individuals have better socio-economic outcomes (Stephens Jr. and Toohey, 2022; Bleakley, 2007; Fogel, 2004; Currie and Madrian, 1999). Existing evidence also suggests that health affects economic outcomes at the national level (Acemoglu and Johnson, 2007; Weil, 2007). A natural question then is whether — and by how much — medical interventions that affect health also affect economic outcomes.

Understanding the effects of medical treatments on economic outcomes may have fundamental implications for health policy. However, rigorous evidence addressing this question is scarce, for at least two reasons. The first is the endogenous assignment of medical treatments. Patients in worse health tend to receive more intensive medical treatments. At the same time, most determinants of health likely affect economic outcomes, making empirical identification challenging. Second, addressing this question requires detailed linked data on individual health, medical treatments, and economic outcomes. The ability to observe these outcomes for an extended period of time is essential to capture any long-run adjustments.

In this paper, we overcome these challenges by investigating the effects of radiation therapy on the mortality and labor market outcomes of breast cancer patients in Denmark. Breast cancer has several features that make it well suited to study the effects of medical treatments. It is the most commonly diagnosed cancer among women, with about 2.2 million new cases worldwide in 2020, accounting for more than 12% of all newly diagnosed cancer cases annually. It is also the most common form of cancer worldwide (OECD, 2023). In addition, roughly one-third of breast cancer patients are diagnosed between the ages of 25–54, which are peak working years for women.<sup>1</sup> Finally, survival rates are high with more than 90% of patients in high-income countries remaining alive 5 years after diagnosis (Arnold et al., 2022).

Denmark constitutes an ideal setting to study the economic effects of radiation therapy for several reasons. To begin with, it has rich clinical and administrative data

---

<sup>1</sup>Authors' own calculation using data from the Global Cancer Observatory of the World Health Organization, available at <https://gco.iarc.fr>, last accessed on 7 February 2024.

that allow us to observe the health and labor market outcomes of the near-universe of breast cancer patients for up to ten years after diagnosis. Second, a change in medical guidelines expanded the eligibility for radiotherapy in January 1995 without affecting the allocation to any other types of breast cancer treatments. This guideline change provides us with plausibly exogenous variation in assignment to treatment, allowing us to address identification challenges.

Using data on women diagnosed with breast cancer between 1990–1998, we show that the guideline change increased the probability of radiation therapy among targeted women by 75.3 percentage points relative to unaffected patients with similar disease characteristics. We then estimate the effects of radiotherapy on patient outcomes through an instrumental variables strategy. The instrument is defined as the interaction between an indicator for belonging to the group of patients with characteristics targeted by the guideline change and a dummy variable for being diagnosed after January 1995. In our setup, almost all patients receive chemotherapy. Thus, our results can be interpreted as the effect of combined radiation and chemotherapy as compared to receiving only chemotherapy.

Given that numerous randomized controlled trials consistently show that breast cancer treatments are effective in reducing mortality (e.g., Early Breast Cancer Trialists' Collaborative Group, 2011, 2005; Overgaard et al., 1997; Ragaz et al., 1997), we first document the effects of radiotherapy on survival. Consistent with prior medical studies, we find that radiation therapy leads to substantial mortality reductions: women who receive combined radiotherapy and chemotherapy are about 10 percentage points less likely to die 5–10 years after diagnosis relative to women who are treated with chemotherapy alone. The mortality gains we estimate using 2SLS are identical to those found in a randomized controlled trial that examined the impact of adding radiotherapy to chemotherapy among women diagnosed with breast cancer ten years earlier (Overgaard et al., 1997). This suggests that the returns to radiotherapy did not diminish during our study period.

We next turn to the effects on our labor market outcomes: employment, income, and welfare use. We address a potential bias from selective survival by coding non-survivors as out of the labor force with no income and no welfare use. We find that radiation therapy has major economic benefits. Our results suggest that women who

receive radiotherapy in addition to chemotherapy are 15.5 percentage points (37%) more likely to be employed ten years after diagnosis. The employment gains are mainly due to a reduction in the likelihood of exiting the labor force. We also find that treatment improves labor earnings by 13–45% and total income by 7–27% in the ten years following cancer diagnosis. The different effects on earnings and total income are due to changes in welfare use. Specifically, we find that radiotherapy mitigates the cumulative risk of being on welfare by 33–41%.

What mechanisms drive these labor market improvements? Given the documented mortality gains, one possibility is that the estimated economic benefits are due to selective survival. We provide four pieces of evidence to suggest that this is not the case. First, we highlight the different dynamics of the estimated effects on mortality versus labor market outcomes: the labor market effects occur before any mortality gains are realized. Second, we consider what the labor market outcomes of non-survivors would need to have been to eliminate our baseline effects. Using a simulation exercise, we find that the outcomes of non-survivors would need to have been in the extreme right tail of the distributions of labor market outcomes among survivors in the treatment group diagnosed in the post-1995 period in order to wipe out the baseline effects. Third, we show that the baseline effects are robust to using only the sample of survivors. Finally, we estimate the effects of radiotherapy on labor market outcomes taking into account selective survival through a Heckman selection model with endogenous covariates (Schwiebert, 2015). The estimates from this model are very similar to the baseline estimates, suggesting that the non-survivors come from the very left part of the distribution of the outcomes.

Reductions in recurrence could be another explanation for the labor market gains. Even if recurrence is not fatal, it could reduce labor supply by inducing incapacitation due to the need for medical treatments. Consistent with prior medical studies documenting reduced cancer recurrence after radiation therapy (Overgaard et al., 1997), we find that radiotherapy reduces the likelihood of recurrence 5-10 years after diagnosis by 14-21 percentage points. However, the patterns of estimated effects on recurrence versus labor market outcomes do not point to a strong link between the two: the reductions in recurrence are experienced during the first few years after diagnosis, but the economic gains are experienced throughout the entire ten years after

diagnosis.

We instead argue that the improved labor market outcomes may reflect a “horizon” effect: with increased life years, individuals must finance additional lifetime consumption which increases worklife (Kalemli-Ozcan and Weil, 2010). Similarly, exogenous improvements in health driven by medical innovations may free up time previously spent on health-related investments and illness and allow individuals to devote more time to the labor market to increase consumption (Jeon and Pohl, 2019). Our administrative data are not suitable to explicitly test the predictions of these theories, but we can confirm that radiotherapy improves general health: it reduces by 20% the number of (inpatient and outpatient) hospital contacts during the 10 years after diagnosis.

Our paper makes two contributions. First, we add to previous studies documenting a pronounced decline in labor supply among survivors of breast cancer compared to those without cancer (e.g., Heinesen and Kolodziejczyk, 2013; Bradley et al., 2005, 2002a,b). Our work complements this as it focuses on whether specific treatment patterns can lessen the impact of the disease on economics outcomes. Second, we contribute to a growing body of work in economics that considers the impact on labor supply of medical treatments.<sup>2</sup> This work has considered antiretroviral therapy for HIV/AIDS patients (Papageorge, 2016; Baranov et al., 2015; Thirumurthy and Graff Zivin, 2012; Habyarimana et al., 2010; Thirumurthy et al., 2008), Cox-2 inhibitors (Butikofer and Skira, 2018; Garthwaite, 2012), mental health treatments (Biasi et al., 2023; Cronin et al., 2020; Timbie et al., 2006), and prescription opioids (Beheshti, 2023; Harris et al., 2020). The impact of breast cancer treatments on labor market outcomes is largely unexplored. One exception is the study by Jeon and Pohl (2019) that uses data from Canada to examine the impact of medical innovation on the labor market outcomes of prostate and breast cancer patients. The paper documents that medical innovation — measured by the number of approved drugs and a patent index — reduced the negative effects of cancer on employment. However, the paper is unable to disentangle the effects of medical innovation from

---

<sup>2</sup>A strand of medical literature examines how cancer treatment patterns, especially for breast cancer, can alter the return to work (e.g., Carlsen et al., 2014; Lindbohm et al., 2014; Damkjæ et al., 2011; Johnsson et al., 2009; Balak et al., 2008; Drolet et al., 2005). These studies rely on multivariate regression models that do not account for selection into treatment.

the improvements in diagnostics as they lack clinical information on disease characteristics. It also estimates only intention-to-treat effects as the authors lack data on the treatments received by patients. In our paper, we estimate the causal effect of a specific and common cancer treatment against a clearly-defined counterfactual. Our ability to examine long-run effects also distinguishes our paper from previous studies.

Insurance providers of all types are increasingly looking at formal cost effectiveness analysis to determine what treatments to cover, benefits design, and price negotiations. In most cases, carriers are making narrow decisions based primarily on medical costs and benefits. The Second Panel on Cost-Effectiveness in Health and Medicine (Sanders et al., 2016) recognized this fact and in their 2016 report, recommended a greater emphasis on the non-medical cost and benefits of treatment. Their goal was to “ensure that all consequences, including those outside the formal health care sector, are considered regularly and comprehensively, which has generally not been the case to date (p. 1096).” The emphasis on non-medical outcomes is especially important in cancer care as treatment like chemotherapy may greatly impact the quality of life. As a result, there is a growing emphasis in oncology care to include quality of life measures as secondary outcomes in cancer treatment clinical trials (Wilson et al., 2015). Despite this, only 45% of National Cancer Institute-sponsored cancer treatment trials with an initial publication about health outcomes subsequently report quality of life outcomes (St Germain et al., 2020). Therefore, obtaining a better understanding the impact of therapies on non-medical outcomes is critically important. This paper helps illustrate how the use of administrative data can be incorporated into medical intervention in order to broaden the set of outcomes.

Finally, our findings are also pertinent to the ongoing discussions on the role of medical treatments in the increase in overall health spending. The costs of cancer treatment are rising worldwide. For example, the United States spent an estimated USD 161.2 billion in 2017 on cancer related healthcare expenditures. In the European Union, healthcare spending for cancer care was EUR 57.3 billion (Jemal et al., 2019). With roughly USD 30 billion in medical costs in 2020, breast cancer has the highest treatment cost among all cancer types (Mariotto et al., 2020). These medical expenditures are expected to increase dramatically in the coming years due to population aging. Our results suggest that breast cancer treatments not only impact

survival but that they have long-term economic benefits, even in a country like Denmark, with its universal health care access, and strong social safety net. As such, they underline the need to consider the potential economic benefits when making decisions on the cost effectiveness of new cancer treatments.

## 2 Institutional Background

This section describes the diagnosis and treatment of breast cancer in Denmark. As we detail below, Denmark has a universal health insurance system that covers almost all health care costs. In addition, there are well-established guidelines on breast cancer care. Therefore, out of pocket expenditures on medical care or uncertainty on the appropriate procedures are unlikely to impact access to treatment. Given our focus on labor market outcomes, we also discuss how the Danish Social Security system insures individuals against income losses from severe health shocks.

### 2.1 Diagnosis and Treatment of Breast Cancer

The majority of Danish health care services, including all stages in the diagnosis and treatment of breast cancer, are free of charge and all residents have equal access. A patient's general practitioner acts as a gatekeeper for specialist treatment. The general practitioner reviews the patient's medical history and conducts a clinical breast exam. If this raises concerns about a potential breast cancer, the patient is referred to a specialist, where she receives a mammography often supplemented with ultrasoundography and needle biopsy.<sup>3</sup>

Patients who are diagnosed with breast cancer receive medical treatments according to the guidelines set by the Danish Breast Cancer Cooperative Group (DBCG).<sup>4</sup>

---

<sup>3</sup>In Denmark, the national breast cancer screening program was rolled out between 2007 and 2010. There were only a few regional screening programs before the introduction of the national plan: in the municipality of Copenhagen (starting from April 1991), in the county of Funen (starting from November 1993), and in the municipality of Frederiksberg (starting from June 1994). All programs offered bi-annual screening to women aged 50 to 69. For more details, see Lynge et al. (2017). In addition, opportunistic screening is rare (Jensen et al., 2005).

<sup>4</sup>DBCG is a multidisciplinary organization founded in 1976 by the Danish Surgical Society in order to standardize breast cancer care across all Danish hospitals (Blichert-Toft et al., 2008).

According to these guidelines, all women diagnosed with early-stage breast cancer (95% of all breast cancer patients; see Møller et al., 2008) are offered primary surgery within two weeks after diagnosis, which consists of either removal of the breast (mastectomy), or breast-conserving surgery where only the tumor is removed (lumpectomy). In both cases, any positive sentinel lymph nodes into which the tumor drains are also removed. After primary surgery, some patients are further offered adjuvant treatment consisting of systemic therapy and/or radiation therapy, depending on their demographic and disease characteristics. Systemic therapies are drugs that spread throughout the body to treat cancer cells. They include chemotherapy, hormonal therapy (endocrine), and immunotherapy (anti-HER2). Radiation therapy is designed to provide highly-targeted treatment to kill any cancer cells that may remain in the breast after surgery. As with other treatments, radiotherapy has some adverse effects. Significant short-term side-effects include pain (Andersen and Kehlet, 2011), fatigue (Minton and Stone, 2008), loss of cognitive function (Debess et al., 2010) and pulmonary and upper limb morbidity (Gomide et al., 2007). Long-term late effects of radiotherapy include an increased risk of ischemic heart disease if the radiation is applied on the left side of the chest (Darby et al., 2013).

In Denmark, there are ongoing national clinical trials on breast cancer treatments at all times. All eligible patients are offered to participate in the trial running at the time of diagnosis.<sup>5</sup> While patients can refuse to participate in trials, in practice this is very rare. Ineligible patients and those who decline to participate receive the standard course of treatment available at the time of diagnosis. Participants in the trial receive treatment according to the guidelines set in the specific trial. The treatment guidelines for systemic therapies and for radiation therapy are determined independently.

Our paper focuses on the period January 1990–December 1998 when the DBCG89 national clinical trial was in place. The trial consisted of four different arms comparing the impact of different chemotherapy treatments for high-risk pre-menopausal and post-menopausal women and of different hormone therapy treatments for high-risk post-menopausal women (see Appendix Figure A1).<sup>6</sup> The allocation to radia-

---

<sup>5</sup>Patients with distant metastases, bilateral carcinomas, those with previous malignancies, and those whose cancer is inoperable are always excluded from clinical trials. Each trial can add additional criteria for exclusion (e.g., age limits).

<sup>6</sup>In addition to the usual exclusion criteria, the clinical trial excluded all patients aged 75 and above.

tion therapy was deterministically tied to clinical and demographic characteristics. DBCG changed the guidelines for use of radiation therapy in the middle of this trial when the results of an earlier clinical trial indicated long-term mortality gains from its use (Møller et al., 2008; Overgaard et al., 1997). Treatment guidelines for systemic therapies were not affected.

Eligibility for radiation therapy during this period is detailed in the decision tree represented in Figure 1. In the decision tree, diagnoses or demographic characteristics are listed in regular font and the text in italics represents the medical decision concerning radiation therapy. The text in bold face represents the new groups that were eligible for radiotherapy after a change in guidelines in 1995. The two numbers in brackets are the number of patients in our sample at each decision node before and after the reforms in 1995.

As the Figure shows, patients who had lumpectomy as primary surgery were eligible to receive radiotherapy regardless of any other demographic or disease characteristics. Among women receiving mastectomies, post-menopausal women are never offered radiation. The guidelines for pre-menopausal patients receiving a mastectomy changed in January 1995. Before January 1995, only pre-menopausal women 45 years of age and younger with at least 4 positive lymph nodes were eligible to receive radiotherapy. After January 1995, eligibility was expanded to all high-risk pre-menopausal women with at least 1 detected positive lymph node or with a tumor of at least 50mm. Our empirical strategy exploits this guideline change as described in Section 4 below.

## 2.2 Income Insurance Against Health Shocks

Working age Danish residents who experience severe health shocks are insured against earnings losses mainly through sickness benefits and disability pension. Sickness benefits compensate for the earnings losses of persons in the labor force. During our study period individuals could receive compensation for up to a year within 36 calendar months. Benefit levels corresponded to 90% of the earnings before the onset of the health shock up to a maximum benefit level per month. During 1984-2000,

---

Around 2.4% of all patients diagnosed with breast cancer between 1990-1998 and who were eligible for the DBCG89 trial refused to participate.

benefits represented on average 65% of lost earnings (Pedersen and Larsen, 2008).

Disability pension provides financial support to those whose ability to work is permanently and substantially reduced. Eligibility is decided by municipal caseworkers taking into account both medical needs and social considerations (Bingley et al., 2012). The disability pension is granted permanently and recipients transition into the old-age pension program when they reach the retirement age. During the period of our analysis there were three different benefit levels depending on the severity of disability. Benefit levels also differed among married and single individuals.<sup>7</sup>

Individuals who are still unable to work after the expiration of sickness benefits but do not qualify for disability pension may receive financial support through unemployment insurance benefits, social assistance benefits or early retirement pension. Appendix Section A1 describes these additional sources of income insurance.

### 3 Data Sources and Analysis Sample

We use several population-level administrative data sets from Denmark. These data include individual-level records with unique personal identifiers, allowing us to follow the entire population over time. We use information for the period 1990 to 2008.

**Treatment Variable.** Our primary data source is the clinical *Breast Cancer Database* collected by the DBCG. These data provide detailed information on patients with invasive breast cancer, including histopathological information (e.g., tumor size, malignancy grade, number of nodes examined, number of tumor positive nodes, estrogen and/or progesterone status), menopausal status, the medical treatments administered (e.g., type of primary surgery, receipt of radiation therapy and of systemic

---

<sup>7</sup>The base level was paid out to individuals whose work capacity was reduced by more than 50% and amounted in 1995 to 6,280 DKK (1,373 USD in 2015 prices) per month for married/cohabiting individuals and 6,531 DKK (1,428 USD) for single individuals. The intermediate group included individuals younger than 60 whose work capacity was reduced to a third as well as individuals aged 60 to 66 years who had no capacity for work. In 1995, married/cohabiting individuals in this group received a monthly pension of 7,143 DKK (1,562 USD) while single individuals received 7,394 DKK (1,616 USD). Finally, individuals younger than 60 with no work capacity were classified as the high level and received 9,634 DKK (2,106 USD) monthly if they were married/cohabiting or 9,885 DKK (2,161 USD) if they were single.

therapy), as well as the date of diagnosis and of major medical interventions (Møller et al., 2008). Using these data, we define an indicator for receipt of radiotherapy.

**Outcome Variables.** Our main health outcome is mortality, obtained from the *Register of Causes of Death*. The register includes death records for all residents who die in Denmark, with information on the exact date and cause of death using the World Health Organization's International Classification of Disease. We measure mortality with indicators for all-cause and breast cancer mortality. We examine effects for each year from the date of diagnosis, up to 10 years after diagnosis.

Our primary labor market outcomes are measures of labor force participation and income. Measures for the former are derived from the *Register-Based Labour Force Statistics*, a dataset based on tax records with records on the labor market status of the entire Danish population as of November. From this data we construct indicators for being employed, unemployed, and out of the labor force. We use the *Income Statistics Register* to construct two measures of income: annual labor earnings (equal to zero for people who are not employed), and gross personal income, which includes government transfers.<sup>8</sup> We study these labor market outcomes for each calendar year from the year of diagnosis up to 10 years later. A final set of outcomes examines effects on government transfers. The data come from *DREAM*, a weekly register of all persons who receive government transfers. We consider four types of payments: sickness leave benefits, welfare benefits paid to unemployed individuals without unemployment insurance, welfare benefits paid to individuals who work reduced hours due to health limitations, and disability benefits. An individual is included in *DREAM* if they receive a benefit for at least one day during the week but the amount of the transfer is not recorded. We define indicators for receipt of any benefits as well as separately for sickness benefits and disability benefits. We also calculate the number of weeks an individual receives these benefits. We construct these variables as cumulative measures for the periods 1–5 and 6–10 years after diagnosis. In order to take into account a potential bias from selective survival, we assign the value one to the out of labor force indicator and zero to all other labor market

---

<sup>8</sup>All monetary variables are expressed in 2015 Danish Kroner. 100 Kroner in 2015 are roughly equivalent to 15 USD in 2015.

outcomes of non-survivors.

**Control Variables.** We observe a rich set of patient characteristics in the clinical *Breast Cancer Database*. Using these data, we construct separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm). From this set, we generate all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically. This allows us to flexibly control for the determinants of radiation therapy eligibility.

Some of our specification checks use additional nationwide registers to construct demographic characteristics of patients at the time of diagnosis. We construct indicators for marital/cohabitation status, immigration status, and level of urbanization of the municipality of residence from the *Population Register*, which provides a snapshot of all residents as of January 1st of each year. In addition, we calculate the number of years of schooling from the *Education Register*, a database with information on the highest level of completed schooling from administrative school records.

**Analysis Sample.** Our analysis sample includes a subset of female breast cancer patients diagnosed between 1990 and 1998. Table 1 details the construction of the analysis sample. Our starting sample includes 26,900 patients. We impose four main restrictions to construct the analysis sample. First, we drop observations on women who were not enrolled in the DBCG89 clinical trial. The primary reasons for exclusion from the trial are contraindications due to old age (61%), previous malignancies (7%), distant metastases (6%), and bilateral carcinomas (4.4%). Second, we restrict our attention to only high-risk pre-menopausal women in order to ensure that our sample is homogeneous in terms of risk classification and menopausal status. We also exclude a small subset of cancer patients who were eligible for radiation therapy regardless of when they were diagnosed, but for whom the intensity of radiotherapy increased if they were diagnosed after 1995. Third, we exclude patients for whom

we have incomplete clinical information on receipt of radiation therapy, tumor size, and on whether the tumor was removed microradically because otherwise we cannot characterize their radiation therapy eligibility status. Finally, we exclude women 55 and older at the time of diagnosis because we need individuals to be below the retirement age 10 years after diagnosis in order to be able to investigate long-term effects on labor market outcomes. The final sample consists of 2,823 observations. In Figure 1, the two numbers in parentheses below each node represent the number of patients in the sample pre- and post-1995 period.

The women in the analysis sample can be divided into three groups. The first group, which we call  $T95$ , includes women with characteristics that make them eligible for radiotherapy only if they are diagnosed after 1995 ( $N = 1,290$ ). These are high-risk pre-menopausal women whose risk classification was not due to only staging, who had a mastectomy, and who were either (i) older than 45 at the time of diagnosis or (ii) younger than 45 with fewer than 4 positive lymph nodes. The second group (*always eligible*,  $N = 874$ ) includes patients who are eligible for radiation therapy regardless of when they are diagnosed. This includes pre-menopausal high-risk patients who had a lumpectomy, as well as pre-menopausal mastectomy patients younger than 45 years of age with at least 4 positive lymph nodes. The last group (*never eligible*,  $N = 659$ ) includes pre-menopausal women who are classified as high-risk only because of a stage II or III ductal carcinoma (i.e., they have tumors smaller than 50mm and no positive lymph nodes). These patients are never eligible to receive radiation therapy during the period under study.

## 4 Empirical Strategy

We are interested in estimating the impact of radiation therapy on health and labor market outcomes of breast cancer patients. The baseline model takes the form:

$$Y_{it}^a = \alpha_1 + RT_{it}\beta_1 + \mathbf{X}_{it}\gamma_1 + u_{1t} + \epsilon_{1it}, \quad (1)$$

where  $Y_{it}^a$  is an outcome observed  $a$  years after the diagnosis of patient  $i$  who was diagnosed with breast cancer in year  $t$ . Our main independent variable,  $RT_{it}$ , is a

variable indicating receipt of radiation therapy.  $\mathbf{X}_{it}$  is a vector of demographic and clinical patient characteristics measured at the time of diagnosis. Finally,  $u_{1t}$  are fixed effects for the type of chemotherapy received (DBCG89 clinical trial arm) and for year of diagnosis.<sup>9</sup> We cluster the standard errors at the hospital level.

The key coefficient of interest in Equation (1),  $\beta_1$ , measures the average difference in the outcomes of breast cancer patients who receive radiation therapy in addition to chemotherapy as compared to those who only receive chemotherapy, after controlling for observed characteristics of the patient. Empirical identification of  $\beta_1$  is complicated since medical treatments are unlikely to be randomly assigned: patients in worse health tend to receive more intensive medical treatments.

In order to address this endogeneity problem, we employ a two-stage least-squares (2SLS) approach that exploits the plausibly exogenous variation in radiation therapy stemming from the 1995 change in guidelines. In particular, we define our instrument as the interaction between an indicator for belonging to the group of breast cancer patients to whom eligibility was expanded in January 1995 ( $T95_i$ ) and a dummy variable for being diagnosed after January 1995 ( $Post95_t$ ). This motivates the following first-stage equation capturing the impact of the proposed instrument on receipt of radiation therapy:

$$RT_{it} = \alpha_2 + T95_i Post95_t \beta_2 + \mathbf{X}_{it} \gamma_2 + u_{2t} + \epsilon_{2it}, \quad (2)$$

and the following reduced-form equation relating the instrument to outcome variables:

$$Y_{it}^a = \alpha_3 + T95_i Post95_t \beta_3 + \mathbf{X}_{it} \gamma_3 + u_{3t} + \epsilon_{3it}, \quad (3)$$

where the vector of patient characteristics  $\mathbf{X}_{it}$  flexibly controls for the determinants of radiotherapy eligibility.<sup>10</sup> Note that our first-stage and reduced-form equations are equivalent to a difference-in-differences model with  $T95$  as the treatment group.

In order for 2SLS to yield consistent estimates of the parameter of interest, three

---

<sup>9</sup>Our sample includes only premenopausal women (because the radiotherapy guidelines changed only for premenopausal women), which were included only in arms B and D of the trial. Therefore, we include fixed effects for these two arms.

<sup>10</sup>The patient characteristics that are flexibly included in  $\mathbf{X}_{it}$  subsume the way in which the treatment group is defined.

conditions must be satisfied. First, the instrument should be a sufficiently-strong determinant of radiation therapy treatment so as to reduce finite-sample bias inherent in 2SLS (the relevance condition). The relevance condition is easily tested using the results of the first-stage equation. Recent research indicates that finite-sample bias is of little concern if the first-stage F-statistic testing the significance of the instrument is greater than 104.7 (Lee et al., 2022).

Second, the instrument needs to be as good as randomly assigned (the exogeneity condition), conditional on observed characteristics. In our difference-in-differences setting, this assumption requires that, given the set of patient characteristics that determine radiotherapy eligibility, the comparison group provides a valid counterfactual for the outcomes that would occur in the treatment group in the absence of the guideline change. While this assumption is not directly testable, we assess its plausibility in several ways. We initially show that the characteristics not tied to radiotherapy eligibility are balanced between the treatment and comparison groups. Second, we plot the dynamics of employment and labor earnings among four groups of women (those in the T95 group diagnosed before and after 1995, and those in the control group diagnosed before and after 1995) and show that all four groups have very similar same pre-diagnosis patterns and levels for both outcomes. Third, we use pre-diagnosis outcomes as the dependent variable in our baseline model and show that there are no differences between the treatment and comparison groups. Finally, we confirm that our results are robust to the comparison group used.

Third, the instrument should affect the outcome of interest only through its effect on the treatment variable (the exclusion restriction). This assumption rules out other guideline changes or public policies that coincide with the 1995 radiation therapy guideline change and target the *T*95 group of patients. This assumption is assured by institutional design: there were no other guideline changes implemented by the DBCG during this period that targeted the patients in the *T*95 group. In addition, the fact that the eligibility for radiotherapy is determined by a set of both clinical and demographic characteristics makes it very unlikely that any other public policy would only affect the women in the treatment group.

If the instrument also satisfies the condition of monotonicity, our instrumental variable strategy will provide the Local Average Treatment Effect (LATE) of ra-

diation therapy for patients who receive radiotherapy due to the expanded eligibility conditions, but would not have received it otherwise (Angrist et al., 1996). The monotonicity condition requires that being diagnosed after 1995 only increases the chance that a patient in the  $T95$  group receives radiation therapy. We cannot interpret the 2SLS as a LATE if eligibility of radiotherapy reduces a patient's likelihood of undergoing radiation therapy, for example, due to congestion effects. Monotonicity cannot be tested formally but we provide evidence of its plausibility in Section 5 by presenting estimates from the first-stage equation in different subsamples. The comparability of the LATE to the average treatment effect in the population depends on the size of the “complier” population. As we will document in Section 5, compliers comprise around 75% of our analysis sample, suggesting that our results are broadly relevant.

## 5 Results

### 5.1 Descriptive Statistics

Table 2 provides descriptive statistics for the overall analysis sample (column 1), for women who receive combined radiation therapy with chemotherapy (column 2) and for those who receive only chemotherapy (column 3).<sup>11</sup> Variable names ending in a question mark are indicators with one being yes and zero being no. The final column reports the  $p$ -value for the test of equality of means between patients receiving and not receiving radiotherapy. About 52% of the patients receive radiation therapy.

Panel A summarizes the demographic characteristics of patients at the time of diagnosis. The average cancer patient in our sample is 43.5 years old with 13 years of schooling. About 70% are married and 84% work in the 2–4 years prior to diagnosis. Patients who receive both chemotherapy and radiotherapy are slightly younger, slightly more educated and substantially less likely to be married at the time of diagnosis relative to patients who receive only chemotherapy. While there is no difference in pre-cancer employment rates between the two groups, the pre-diagnosis income

---

<sup>11</sup> Appendix Table A1 provides these descriptives separately for women diagnosed with breast cancer before and after the radiotherapy guideline change.

and labor earnings of women receiving radiotherapy are 4–5% higher.

Panel B focuses on disease pathology. The statistics suggest that patients who undergo radiotherapy tend to have substantially worse clinical characteristics. Their average tumor size is 14% larger than the average tumor size of those who only receive chemotherapy. This is primarily due to the higher share of tumors larger than 50mm among patients treated with radiation therapy. Radiotherapy patients also have a higher average number of lymph nodes that contain cancer. This is not surprising given that during the initial part of our analysis period, only patients with at least 4 positive nodes were eligible to receive radiotherapy. Similarly, the near-universe of patients who do not receive radiation therapy have mastectomy as the primary surgery because lumpectomy patients are always eligible to receive radiotherapy.

Panels C presents the post-diagnosis health outcomes for the different subsamples. Given the negative selection of patients into different treatment regimens, it is not surprising that mortality is significantly higher among patients who receive radiotherapy combined with chemotherapy. Mortality differences appear as early as one year after diagnosis and grow over time. 10 years after diagnosis, the mortality rate of radiotherapy patients is 5 percentage points higher than the mortality rate of women who do not receive radiation therapy. These mortality differences are almost entirely driven by mortality from breast cancer.

Panel D describes the labor market outcomes. The summary statistics suggest that radiotherapy patients tend to have worse labor market performance. They are less likely to be employed and more likely to be out of the labor force. While their labor earnings and total income remain higher, the difference relative to the group of patients who only receive chemotherapy declines over time. The differences in these outcomes are small in magnitude and generally not statistically significant. In contrast, there are economically large differences in welfare use between the two groups, with radiotherapy patients receiving government transfers at much higher rates.

The raw correlations described in Table 2 show that radiotherapy patients are the highest risk patients and it is therefore no surprise that, in raw averages, they have the highest cancer mortality. Identifying the complete set of characteristics that determine mortality and are correlated with radiotherapy is unlikely to eliminate concerns about omitted variables bias. To form a baseline case, we estimate the relationship

between radiation therapy and the mortality of cancer patients using OLS (see Appendix Table A2). The results indicate no correlation with mortality in the short-run but statistically significant mortality declines starting from five years after diagnosis. For example, we find that radiation therapy is associated with a 5.6 percentage point decline in all-cause mortality five years after diagnosis. This association grows to 6.8 percentage points after ten years. The mortality gains are due to a reduction in breast cancer mortality. Even though controlling for observable characteristics reverses the sign of the association between radiation therapy and patient outcomes, the results raise the concern that the same could hold for other, unobserved characteristics, and that the estimated associations are biased because of these omitted variables.

For completeness, we also estimate OLS models for the relationship between radiation treatment and labor market outcomes. Recall that we assign the value one to the out of labor force indicator and zero to all other labor market outcomes of non-survivors to address a potential bias from selective survival. The OLS associations suggest a weak relationship between radiation therapy and the likelihood of dropping out of the labor force, in both statistical significance and magnitude, starting from three years after cancer diagnosis. While radiotherapy is also consistently positively associated with the likelihood of being employed and both of our measures of income, these associations are generally not statistically significant at conventional levels. Similarly the OLS results indicate a consistently negative but generally statistically insignificant relationship between radiation therapy and the likelihood of receiving government transfers (see Appendix Table A3).

In the next section, we turn to our quasi-experimental approach that leverages the variation in radiation therapy stemming from the 1995 change in guidelines.

## 5.2 Effects of Radiation Therapy on Mortality and Labor Market Outcomes

We first provide visual evidence on the first-stage relationship between the 1995 radiotherapy guideline change and the likelihood of receiving radiotherapy. Given that the women impacted by the eligibility expansion and those in the comparison group (i.e., remaining high-risk pre-menopausal women) differ along clinical and demographic

characteristics by design, we present in Figure 2 the regression-adjusted probability of receiving radiation therapy by year of diagnosis. Specifically, we regress the indicator for receipt of radiation therapy on the characteristics that determine radiotherapy eligibility, separately for  $T95$  and the comparison group, and then plot the average of the residuals from these regressions for women diagnosed in the year indicated on the horizontal axis. The solid line represents the women in  $T95$  while the dashed line represents the group of women who are never or always eligible for treatment.

Figure 2 shows that take-up of radiotherapy is constant among the comparison group throughout the entire period. In contrast, take-up in the  $T95$  group is fairly stable before and after the 1995 guideline change with a sharp level shift in 1995.<sup>12</sup> Consistent with the visual evidence, the regression estimate for the first-stage relationship between the instrument and treatment take-up, based on Equation (2), is economically large and highly statistically significant. In particular, we find that the 1995 guideline change led to an increase of 75.3 percentage points (s.e. 1.8) in the probability of radiotherapy among women in the  $T95$  group relative to other high-risk pre-menopausal patients (see Column 1 of Table 3). The associated F-statistic is 1,842.3, well above the recent rule-of-thumb value of roughly 100 to minimize finite sample bias (Lee et al., 2022).

We next turn to effects on mortality. Figure 3 plots the 2SLS coefficients on the indicator for radiotherapy and corresponding 95% confidence intervals from separate models with the mortality indicators as outcomes, measured at the time indicated on the horizontal axis. Circles represent effects on all-cause mortality and triangles represent effects on breast cancer mortality. Regression coefficients corresponding to Figure 3 are provided in the first two rows of Appendix Table A4, while the first two rows in Appendix Table A5 present regression coefficients on the instrument from the reduced-form Equation (3).

The results suggest that radiation therapy leads to substantial mortality reductions. The benefits appear as early as three years post diagnosis and the coefficients are statistically significant at the 5% level starting from five years after cancer diag-

---

<sup>12</sup> Appendix Figure A2(a) provides the corresponding figure based on raw data. Figure 2 shows that take-up of radiotherapy among  $T95$  women increases already in 1994. Appendix Figure A2(b) shows that this is due to an increase in the last two quarters of 1994 when some hospitals adopted the new guidelines before the official enactment date. Our results are robust to excluding 1994.

nosis. Women who receive combined radiotherapy and chemotherapy are about 10 percentage points less likely to die 5–10 years after diagnosis relative to women who are treated with chemotherapy alone, representing 35–60% reductions relative to the mean mortality among the untreated patients. The reduction in all-cause mortality is entirely driven by the reduction in breast cancer mortality.

Having established the mortality gains from radiotherapy, we next plot in Figure 4 the 2SLS coefficients on the indicator for radiotherapy and corresponding 95% confidence intervals from separate models with labor market outcomes, measured at the time indicated on the horizontal axis. Corresponding regression coefficients are provided in rows 3–7 of Appendix Table A4 and the reduced-form results are presented in rows 3–7 of Appendix Table A5. In Figure 4(a), circles, triangles and crosses represent effects on the likelihood of being employed, unemployed, and out of the labor force, respectively. We provide estimates from four years before through 10 years after diagnosis. If the assumptions of our difference-in-difference model are correct, we should see little effect in the four pre-diagnosis years. We find that radiation therapy leads to statistically significant increases in the probability of employment. The magnitudes are sizeable ranging from 8.6 percentage points (11% at the mean) in the first year after diagnosis to 15.5 percentage points (37%) ten years after. The rise in employment is entirely due to a reduction in the likelihood of exiting the labor force.

Figure 4(b) focuses on our measures of income, with circles representing effects on annual labor earnings and triangles representing effects on gross personal income (including government transfers). Consistent with the results on employment, we find that receipt of radiotherapy leads to an increase in annual labor earnings of about DKK 25,864–65,107 (USD 3,845–9,679) and in annual gross personal income of about DKK 18,745–62,744 (USD 2,787–9,327) during the ten years following cancer diagnosis. These are economically large gains representing 13–45% of average annual labor earnings and 7–27% of average gross personal income.

Focusing on the coefficients in the pre-diagnosis periods in Figure 4, there is no persistent pattern in the results and only one of the 20 coefficients is statistically significant, a result expected due to chance with a  $p$ -value of 0.05.

The fact that the gains in labor earnings are higher than those in total income is consistent with the compensating role of income insurance in Denmark that par-

tially covers for the lost earnings of individuals who experience severe health shocks. For this reason, we provide in Table 4 evidence on the effects of radiation therapy on government transfers.<sup>13</sup> The 2SLS results indicate that women who receive radiation therapy are about 10 percentage points less likely to receive government transfers during the first 10 years after they are diagnosed with cancer. This is a large effect considering that around 33–41% of untreated women receive government transfers. The reduction in the likelihood of receiving government transfers is mainly driven by a decline in the receipt of sickness benefits (i.e., a fall in the likelihood of being on sick leave). The estimated effects on the likelihood of being on disability insurance are large but not statistically significant. Similarly, the effect sizes at the intensive margin are economically large, with the average number of weeks on government transfers falling by 3.5–9 weeks (relative to means of 28–31 weeks), but only the effect on the number of weeks on sickness benefits is marginally statistically significant.

### 5.3 Comparing the Estimated Effects to the Existing Literature

The DBCG82 clinical trial examined the impact of adding radiotherapy to chemotherapy among high-risk pre-menopausal women diagnosed with breast cancer between 1982–1989. How do our estimated mortality effects compare to those documented in the DBCG82 randomized clinical trial that led to the 1995 guideline change? Overgaard et al. (1997) report that the 10-year mortality rate among women randomized to receive radiation therapy in addition to chemotherapy was 9 percentage points lower than among women who received only chemotherapy. The fact that the mortality gains we estimate using 2SLS are almost identical to those found in an earlier randomized control trial raises confidence in the validity of the key identification assumptions in our observational study. In addition, the mortality gains are identical to the gains observed in women treated 10 years earlier, which suggests that the returns to radiotherapy did not diminish during this period.

Our results suggest that radiation therapy has major economic benefits: it increases the probability of employment by 11–38%, it improves labor earnings by 13–45%, and it mitigates the cumulative risk of being on welfare by 33–41%. These

---

<sup>13</sup> Appendix Table A6 provides the corresponding reduced-form estimates.

effect sizes are generally comparable to those found in other studies evaluating the economic effects of medical treatments. For example, Biasi et al. (2023) focused on the pharmaceutical treatment of bipolar disorder and find that access to lithium by age 20 increases labor market participation by 30% and earnings by 26%. Garthwaite (2012) found that Cox-2 inhibitors, medications used in the treatment of chronic pain and inflammation, increase the likelihood of working by 22 percentage points relative to a mean of almost 40%. Butikofer and Skira (2018) documented that the market entry of Vioxx, a popular Cox-2 inhibitor, reduced the number of sickness leave days among individuals with joint pain by 7–12% while its removal from the market increased sickness absence days by 12–16%.

It may also be helpful to benchmark our estimates against the effects of breast cancer on women’s labor market outcomes. Among all Danish women aged 21–54 during 1990–1998, the difference between the employment rate of women with and without breast cancer ranges from 5–22 percentage points one to ten years after diagnosis. These employment gaps are larger than those found in the United States (Bradley et al., 2002a,b) but comparable to those documented in Denmark in prior studies (Heinesen and Kolodziejczyk, 2013). Overall, our results imply that radiation therapy can reduce the long-run employment gap by around 70%.

## 5.4 Instrument Validity and Robustness Checks

The 2SLS method yields consistent estimates if the instrument satisfies the relevance assumption, the exogeneity assumption, and the exclusion restriction. The change in guidelines has an economically large and statistically significant effect on radiotherapy take-up, so we can safely conclude that the relevance assumption is satisfied.

The exogeneity assumption requires that the comparison group provide a valid counterfactual for the time path of the outcomes of women in the *T95* group in the absence of the guideline change. We bring suggestive evidence on the plausibility of this assumption in several ways. First, we examine the observable characteristics of women in the *T95* and in the comparison group who are diagnosed before the guideline change (see Appendix Table A7). Since the 1995 guideline change targeted patients based on clinical characteristics and age at diagnosis, we not surprisingly find

differences between women in the  $T95$  and in the comparison group along these dimensions. However, when we compare the characteristics that are not tied to radiotherapy eligibility, we find relatively small and generally statistically insignificant differences. In the cases when the differences are statistically significant (employment status, years of education), they are economically small.

Second, we plot the raw data on the evolution of labor market outcomes.<sup>14</sup> We observe each patient's outcomes for a total of 15 years: four years prior to diagnosis, the diagnosis year, and 10 years after. We combine patients into four different groups: women in the  $T95$  group diagnosed before and after 1995, and women in the control group diagnosed over the same periods. We then generate means by year in relation to diagnosis. Figure 5 presents the results. We find that all four groups have very similar pre-diagnosis patterns and levels for all outcomes. All groups experience a decline in employment and earnings after diagnosis. The pre-1995  $T95$  group has a more severe decline in employment and earnings after diagnosis so the treatment effects we are estimating are generated by these negative events not occurring. The large decline in economic outcomes for the  $T95$  group diagnosed in the pre-1995 period is not surprising — as discussed before, these women have worse clinical characteristics and are older on average.

Third, we estimate our baseline model using pre-diagnosis outcomes as the dependent variable.<sup>15</sup> We report these estimates in Figure 4(a) for employment, unemployment, and out of the labor force, and in Figure 4(b) for labor and total income. There are 20 pre-diagnosis parameters and only one is statistically different from zero (3 years before diagnosis in unemployment) which is the expected Type II error rate for a  $p$ -value of 0.05. In general, there are little persistent pre-treatment trends in the outcomes that appear to be contaminating the post diagnosis results.<sup>16</sup>

We next turn to the exclusion restriction. In our setup, this assumption implies

---

<sup>14</sup>We are unable to produce these graphs for welfare use as the data on government transfers begins in 1991.

<sup>15</sup>Since everyone lives until the year of diagnosis, we cannot estimate these models for mortality. We are also unable to examine effects on pre-diagnosis welfare use as the data on government transfers begins in 1991.

<sup>16</sup>We also estimated our baseline model using demographic characteristics that are not tied to radiation therapy eligibility as the dependent variable. The results presented in Appendix Table A8 indicate no statistically significant effects on these predetermined characteristics.

that the radiotherapy guideline change is the only factor that can affect the outcomes of women in the  $T95$  group after 1995. As noted, this assumption is assured due to the institutional setup. Women in our sample are part of an ongoing randomized control trial and we have information on the systemic therapies they received. In order to provide suggestive evidence on the plausibility of this assumption we further estimate a placebo regression: we restrict the sample to women in the always- and never-treated groups, we assume that the always-treated group experience the medical guideline change and we re-estimate our reduced-form regressions. If our baseline estimates pick up an improvement in the outcomes of women diagnosed after 1995 unrelated to the effectiveness of radiotherapy (but possibly correlated with the receipt of radiotherapy), then we would likely see an association between the guideline change and the outcomes of always-eligible women as well. However, we find no evidence that the guideline change led to statistically significant differences in the outcomes of always-eligible women relative to never-eligible women (see Appendix Figure A3). In addition, the estimated effects have the wrong sign and are substantially smaller in absolute value than our baseline reduced-form estimates: by a factor of 2-3 in the case of income and 11-16 in the case of employment and labor force participation.

Finally, we discuss the validity of the monotonicity assumption, which allows us to interpret our results as LATE of radiation therapy. Monotonicity requires that the 1995 guideline change only increases the likelihood of a patient receiving treatment. This assumption would be violated if the expansion of eligibility for radiotherapy reduced the likelihood of undergoing radiation therapy for some, for example, due to congestion effects. Intuitively, we do not expect such a violation to be present in our sample because radiotherapy is provided in a handful of locations with large treatment capacities. For example, in 2007, six radiotherapy centers provided a total of 220,000 treatments (Olsen et al., 2007). The radiotherapy guideline expanded the number of cancer patients eligible for treatment by 500. Each of these patients were eligible to receive 20–25 treatments, corresponding to a 6% increase in treatment demand based on the treatment capacity in 2007.

Formally, a violation of the monotonicity assumption implies that the first-stage coefficient on the guideline change indicator is negative for certain patients. In the

spirit of Mueller-Smith (2015), we estimate the first stage across subgroups defined by education, pre-diagnosis income, marital status, and predicted mortality risk. The results presented in Table 3 show that the estimated first-stage coefficient is remarkably stable in magnitude across all these subgroups.

In the remainder of the section, we examine the robustness of the 2SLS estimates to alternative modeling choices and to alternative ways of constructing the analysis sample. The results are presented in Appendix Figures A4 and A5.<sup>17</sup> We start by examining the sensitivity of the results to the inclusion of additional controls. If the exogeneity assumption holds (i.e., there are no systematic differences between the *T95* and the control group beyond the characteristics determining radiotherapy eligibility), adding more covariates should not change our baseline estimates. Our estimates are very similar when we include additional demographic characteristics (years of schooling, marital status, immigration status, level of urbanization of residence), the average of outcomes two to four years before diagnosis, or hospital fixed effects.<sup>18</sup> We next check if the way we selected the analysis sample has any influence on our estimates and show that the estimates are robust when we exclude (i) women diagnosed in 1994, the year when some hospitals already adopted the revised guidelines, (ii) women residing in areas where breast cancer screening programs were piloted, and (iii) women who received lumpectomy as primary surgery.<sup>19</sup> Finally, we explore the sensitivity of the results to the choice of the control group and confirm that the results are robust to using either always-eligible or never-eligible women as a control group alone.

It is important to emphasize that the key identifying assumptions of 2SLS are ultimately untestable and we can never rule out all scenarios that can lead to their violation. On their own, none of the checks described above is sufficient to claim the validity of the 2SLS assumptions. However, taken together they provide consistent evidence that these assumptions are likely to hold in our context, and suggest that

---

<sup>17</sup>To enhance readability, we present estimates grouped 1-5 years after diagnosis and 6-10 years after diagnosis, rather than providing yearly estimates since diagnosis.

<sup>18</sup>Our inference is also robust to alternative levels of clustering. In particular, we confirm that our results (available upon request) are not sensitive to clustering at the level of age at diagnosis or the health care region in which the patient resides.

<sup>19</sup>Our results are also similar when excluding women diagnosed with breast cancer in the last two quarters of 1994 or who were treated in hospitals that implemented the new guidelines early.

our model is likely to yield causal estimates of radiation therapy.

## 5.5 Potential Mechanisms Behind the Labor Market Improvements

Given the large gains documented for both mortality and labor market outcomes, a natural question is whether the improvements in economic outcomes may be driven by selective survival. We provide four pieces of evidence to suggest that this is not the case. First, we note that the labor supply effects appear from the first years after diagnosis when the large mortality benefits have not yet been realized.

Second, we ask what the labor market outcomes of non-survivors would need to have been to eliminate our baseline effects. In particular, we eliminate the mortality gains from radiotherapy by randomly selecting a number of non-survivors in the  $T95$  group in the pre-intervention period (before 1995).<sup>20</sup> The number of selected non-survivors corresponds to the estimated mortality decline for that period (e.g., 5 or 10 years after diagnosis). We then assign to these re-coded non-survivors a labor market outcome based on a specific value in the distribution among survivors in the  $T95$  group in the post-period (after 1995) and re-estimate our baseline specification. We repeat these steps 100 times and save the estimated effects. We repeat the procedure for multiple points along the distribution among survivors in  $T95$  in the post-period: we use employment rates between 0–100 percent and 0–90th percentiles of labor earnings in steps of 10 percentiles. Finally, we plot the average of the estimated effects and the corresponding 95% confidence intervals against the values chosen for the outcomes of non-survivors. We find that when the outcomes of non-survivors are the same as the average employment rate or median labor income of survivors in  $T95$  in the post-1995 period, the estimated effect sizes are reduced to around 40% of the baseline estimates but are still statistically and economically significant. In all cases, the effects of radiotherapy are eliminated only if non-survivors are drawn from the extreme right tail of the distributions (see Appendix Figure A6).

---

<sup>20</sup>This procedure is similar to one used by Bharadwaj et al. (2013), who examine whether the test scores gains from medical treatments received by very low birth weight infants are due to selective mortality. For brevity, we report the results for two of our main outcomes: employment and labor earnings, 5 and 10 years after diagnosis.

Third, we show that the baseline effects on labor market outcomes are not due to the fact that non-survivors are recorded to have no employment and no income. To that end, we estimate our baseline model using only survivors and show that these estimates are similar to our main results (see Appendix Table A9).

Finally, we explicitly model the role of mortality in determining labor market outcomes by estimating a Heckman selection model via the control function approach, using a procedure suggested by Schwiebert (2015). This requires that we have variation that determines mortality but not labor supply. To this end, we add to the mortality equation (the selection equation) the triple interactions between the  $T95$  indicator, the  $Post95$  indicator, and (i) an indicator for having a tumor larger than 5cm, or (ii) indicators for the type of surgery (i.e., breast conserving or mastectomy). These variables strongly predict mortality but should not necessarily be predictive of labor supply.<sup>21</sup> The effects of radiation therapy on labor market outcomes estimated through this method are slightly smaller than our baseline estimates 5 years after diagnosis, but of virtually the same magnitude 10 years after diagnosis (see Appendix Table A9). This suggests that the non-survivors in the  $T95$  group diagnosed before 1995 come from the left tail of the distributions of labor market outcomes.

We next consider whether some of the labor supply effects could be driven by recurrence. If treatment reduces recurrence, even if the re-emergence of cancer is not fatal, it could reduce labor supply. Overgaard et al. (1997) report that radiation therapy reduces the cumulative risk of recurrence ten years after diagnosis by 21 percentage points. We find that radiotherapy reduces the likelihood of recurrence 5-10 years after diagnosis by 14-21 percentage points in our sample.<sup>22</sup> In order to check whether recurrence may drive the labor market exits, we use recurrence in a given year as the outcome in our baseline model and compare the effect of radiotherapy on

---

<sup>21</sup>For computational reasons, we also need to replace the full set of interactions between the indicators for clinical characteristics determining radiotherapy eligibility with the  $T95$  indicator, and the set of year-of-diagnosis fixed effects with the  $Post95$  indicator. This change leaves our baseline results virtually unchanged (see Appendix Table A9). The full details of the Heckman model are given in Appendix Section A2.

<sup>22</sup>The clinical data from DBCG does not include full information on recurrence as follow-up is incomplete. In order to create a consistent measure of recurrence, we supplement the DBCG data when there is no follow-up with hospital discharge data and classify a patient as experiencing recurrence in a given year if they are flagged in the clinical data or if they have an inpatient admission for breast cancer in that year.

recurrence to its effects on employment and labor force participation. We find that the estimated effects have very different patterns. For example, most of the reduction in recurrence occurs in the first two years after diagnosis, while the employment and income benefits tend to be experienced throughout the entire period (see Appendix Figure A7). This suggests that recurrence may have a limited role in explaining the labor market benefits of radiation therapy.

What then might explain the effects on labor market outcomes? We argue that there is a simple economic answer as to why labor market outcomes improve.<sup>23</sup> Dynamic models of retirement show that a reduction in mortality will, holding all else constant, typically lead to a later retirement age (Chen and Lau, 2016; Bloom et al., 2014; Kalemli-Ozcan and Weil, 2010). Kalemli-Ozcan and Weil (2010) label this the “horizon” effect which is simply that with increased life years, individuals must finance additional lifetime consumption which increases worklife.

Models specific to cancer treatment suggest this same pattern of results between increased life expectancy and time at work. Jeon and Pohl (2019) attempt to explain the negative effects of a breast cancer diagnosis on labor market outcomes by building a Grossman-style model (Grossman, 1972) where time can be spent in work, home production, investing in health, or unproductive sick time. Exogenous improvements in health via technology free up time investing in health and time spent sick. As this increases full income, and assuming consumption is a normal good, this would encourage individuals to allocate more time to the labor market so as to increase consumption.

While we do not have suitable outcomes from administrative data to explicitly test the predictions of Jeon and Pohl (2019), we shed light on the possibility that radiotherapy improves general health by examining its effects on (inpatient and outpatient) hospital contacts. In particular, we calculate the cumulative number of inpatient and outpatient contacts since diagnosis, using the exact dates of diagnosis and

---

<sup>23</sup>We also considered whether additional treatments may offer mental health benefits. Unfortunately, we are not able to test this with the administrative data as information on mental health care utilization starts only in 1995. The existing literature on this topic, however, suggests that it may not play a large role: previous RCTs show no differences in key nonclinical outcomes such as quality of life, pain, body image, anxiety or depression for those treated with or without radiotherapy (Velikova et al., 2018; Pignol et al., 2016; Rayan et al., 2003; Whelan et al., 2000).

hospital visits, and use this as the outcome in the baseline equation. As before, we assign zero visits to non-survivors after death. Consistent with our conjecture, we find sizable reductions in visits: radiotherapy leads to 2.6 (20%) fewer hospital contacts during the 10 years after diagnosis (see Appendix Figure A8).

## 6 Conclusions

This paper uses rich clinical and administrative data from Denmark to study the effects of radiation therapy on the mortality and labor supply of breast cancer patients. In order to identify the causal effects, we exploit variation in radiotherapy eligibility stemming from a medical guideline change in 1995. We find that patients who receive combined chemotherapy and radiotherapy are significantly less likely to die relative to patients who are only treated with chemotherapy. Our results suggest that radiation therapy reduces the likelihood of death by roughly 35% within the ten years after diagnosis. We next examine the effects of treatment on labor market outcomes and find that radiation therapy has major economic benefits. Our findings indicate that, ten years after diagnosis, treated women are 37% more likely to be employed and earn 45% more than untreated patients. We also find some evidence that treated patients are less likely to rely on welfare, with treatment reducing the cumulative risk of receiving government transfers ten years after diagnosis by 10 percentage points. Finally, we provide suggestive evidence that the labor market benefits of radiotherapy are not due to selective survival or the incapacitation effects of recurrence, but rather to the fact that women are in better health, which encourages them to spend more time in the labor market so as to increase consumption.

Given that an increasing share of breast cancer patients are diagnosed during their working years, understanding the effects of cancer treatments on socio-economic outcomes becomes even more important. Taken together, our results suggest that cancer treatments not only impact survival but also lead to large economic gains which should be considered when assessing the cost-effectiveness of new cancer treatments.

## References

- Acemoglu, Daron, and Simon Johnson. 2007. "Disease and Development: The Effect of Life Expectancy on Economic Growth." *Journal of Political Economy* 115 (6): 925–985.
- Andersen, Kenneth Geving, and Henrik Kehlet. 2011. "Persistent Pain after Breast Cancer Treatment: A Critical Review of Risk Factors and Strategies for Prevention." *Journal of Pain* 12 (7): 725–746.
- Angrist, Joshua D., Guido W. Imbens, and Donald B. Rubin. 1996. "Identification of Causal Effects Using Instrumental Variables." *Journal of the American Statistical Association* 91 (434): 444–455.
- Arnold, Melina, Eileen Morgan, Harriet Rumgay, Allini Mafra, Deependra Singh, Mathieu Laversanne, Jerome Vignat, et al. 2022. "Current and Future Burden of Breast Cancer: Global Statistics for 2020 and 2040." *Breast: Official Journal of the European Society of Mastology* 66:15–23.
- Balak, Fulya, Corné A. M. Roelen, Petra C. Koopmans, Elike E. ten Berge, and Johan W. Groothoff. 2008. "Return to Work after Early-Stage Breast Cancer: A Cohort Study into the Effects of Treatment and Cancer-Related Symptoms." *Journal of Occupational Rehabilitation* 18 (3): 267–272.
- Baranov, Victoria, Daniel Bennett, and Hans-Peter Kohler. 2015. "The Indirect Impact of Antiretroviral Therapy: Mortality Risk, Mental Health, and HIV-negative Labor Supply." *Journal of Health Economics* 44:195–211.
- Beheshti, David. 2023. "The Impact of Opioids on the Labor Market: Evidence from Drug Rescheduling." *Journal of Human Resources* 58 (6): 2001–2041.
- Bharadwaj, Prashant, Katrine Vellesen Løken, and Christopher Neilson. 2013. "Early Life Health Interventions and Academic Achievement." *American Economic Review* 103 (5): 1862–1891.
- Biasi, Barbara, Michael S Dahl, and Petra Moser. 2023. "Career Effects of Mental Health: Evidence from an Innovation in Treating Bipolar Disorder," 2023.
- Bingley, Paul, Nabanita Datta Gupta, and Peder J. Pedersen. 2012. "Disability Programs, Health, and Retirement in Denmark since 1960." Edited by David A. Wise. In *Social Security Programs and Retirement around the World: Historical Trends in Mortality and Health, Employment, and Disability Insurance Participation and Reforms*, chapter 5, 217–249. University of Chicago Press.
- Bleakley, Hoyt. 2007. "Disease and Development: Evidence from Hookworm Eradication in the American South." *Quarterly Journal of Economics* 122 (1): 73–117.

- Blichert-Toft, Mogens, Peer Christiansen, and Henning T. Mouridsen. 2008. “Danish Breast Cancer Cooperative Group – DBCG: History, Organization, and Status of Scientific Achievements at 30-Year Anniversary.” *Acta Oncologica* 47 (4): 497–505.
- Bloom, David E., David Canning, and Michael Moore. 2014. “Optimal Retirement with Increasing Longevity.” *Scandinavian Journal of Economics* 116 (3): 838–858.
- Bradley, Cathy J, Heather L Bednarek, and David Neumark. 2002a. “Breast Cancer and Women’s Labor Supply.” *Health Services Research* 37 (5): 1309–1328.
- . 2002b. “Breast Cancer Survival, Work, and Earnings.” *Journal of Health Economics* 21 (5): 757–779.
- . 2005. “Short-Term Effects of Breast Cancer on Labor Market Attachment: Results from a Longitudinal Study.” *Journal of Health Economics* 24 (1): 137–160.
- Butikofer, Aline, and Meghan M. Skira. 2018. “Missing Work Is a Pain: The Effect of Cox-2 Inhibitors on Sickness Absence and Disability Pension Receipt.” *Journal of Human Resources* 53 (1): 71–122.
- Carlsen, Kathrine, Marianne Ewertz, Susanne Oksbjerg Dalton, Jens Henrik Badsberg, and Merete Osler. 2014. “Unemployment among Breast Cancer Survivors.” *Scandinavian Journal of Public Health* 42 (3): 319–328.
- Chen, Yanyou, and Sau-Him Paul Lau. 2016. “Mortality Decline, Retirement Age, and Aggregate Savings.” *Macroeconomic Dynamics* 20 (3): 715–736.
- Cronin, Christopher J., Matthew P. Forsstrom, and Nicholas W. Papageorge. 2020. “What Good Are Treatment Effects without Treatment? Mental Health and the Reluctance to Use Talk Therapy.” NBER Working Paper no. 27711.
- Currie, Janet, and Brigitte C. Madrian. 1999. “Health, Health Insurance and the Labor Market.” Edited by Orley C. Ashenfelter and David Card. In *Handbook of Labor Economics*, 3309–3416. Vols. 3, part C. Elsevier.
- Damkjæ, Lars Henrik, Isabelle Deltour, Nis Palm Suppli, Jane Christensen, Niels T. Kroman, Christoffer Johansen, and Susanne Oksbjerg Dalton. 2011. “Breast Cancer and Early Retirement: Associations with Disease Characteristics, Treatment, Comorbidity, Social Position and Participation in a Six-Day Rehabilitation Course in a Register-Based Study in Denmark.” *Acta Oncologica* 50 (2): 274–281.

- Darby, Sarah C., Marianne Ewertz, Paul McGale, Anna M. Bennet, Ulla Blom-Goldman, Dorthe Brønnum, Candace Correa, et al. 2013. "Risk of Ischemic Heart Disease in Women after Radiotherapy for Breast Cancer." *New England Journal of Medicine* 368 (11): 987–998.
- Debess, Jeanne, Jens Østergaard Riis, Malene Cramer Engebjerg, and Marianne Ewertz. 2010. "Cognitive Function after Adjuvant Treatment for Early Breast Cancer: A Population-Based Longitudinal Study." *Breast Cancer Research and Treatment* 121 (1): 91–100.
- Drolet, Mélanie, Elizabeth Maunsell, Myrto Mondor, Chantal Brisson, Jacques Brisson, Benoît Mâsse, and Luc Deschênes. 2005. "Work Absence after Breast Cancer Diagnosis: A Population-Based Study." *Canadian Medical Association Journal* 173 (7): 765–771.
- Early Breast Cancer Trialists' Collaborative Group. 2005. "Effects of Radiotherapy and of Differences in the Extent of Surgery for Early Breast Cancer on Local Recurrence and 15-Year Survival: An Overview of the Randomised Trials." *Lancet* 366 (9503): 2087–2106.
- . 2011. "Effect of Radiotherapy after Breast-Conserving Surgery on 10-Year Recurrence and 15-Year Breast Cancer Death: Meta-Analysis of Individual Patient Data for 10 801 Women in 17 Randomised Trials." *Lancet* 378 (9804): 1707–1716.
- Fogel, Robert William. 2004. *The Escape from Hunger and Premature Death, 1700–2100: Europe, America, and the Third World*. Cambridge Studies in Population, Economy and Society in Past Time. Cambridge: Cambridge University Press.
- Garthwaite, Craig L. 2012. "The Economic Benefits of Pharmaceutical Innovations: The Case of Cox-2 Inhibitors." *American Economic Journal: Applied Economics* 4 (3): 116–137.
- Gomide, L. B., J. P. C. Matheus, and F. J. Candido dos Reis. 2007. "Morbidity after Breast Cancer Treatment and Physiotherapeutic Performance." *International Journal of Clinical Practice* 61 (6): 972–982.
- Grossman, Michael. 1972. "On the Concept of Health Capital and the Demand for Health." *Journal of Political Economy* 80 (2): 223–255.
- Habyarimana, James, Bekezela Mbakile, and Cristian Pop-Eleches. 2010. "The Impact of HIV/AIDS and ARV Treatment on Worker Absenteeism: Implications for African Firms." *Journal of Human Resources* 45 (4): 809–839.

- Harris, Matthew C., Lawrence M. Kessler, Matthew N. Murray, and Beth Glenn. 2020. "Prescription Opioids and Labor Market Pains: The Effect of Schedule II Opioids on Labor Force Participation and Unemployment." *Journal of Human Resources* 55 (4): 1319–1364.
- Heckman, James. 1974. "Shadow Prices, Market Wages, and Labor Supply." *Econometrica* 42 (4): 679–694.
- Heinesen, Eskil, and Christophe Kolodziejczyk. 2013. "Effects of Breast and Colorectal Cancer on Labour Market Outcomes—Average Effects and Educational Gradients." *Journal of Health Economics* 32 (6): 1028–1042.
- Jemal, Ahmedin, Lindsey Torre, Isabelle Soerjomataram, and Freddie Bray, eds. 2019. *The Cancer Atlas*. Third edition. Atlanta: American Cancer Society.
- Jensen, Allan, Anne Helene Olsen, My von Euler-Chelpin, Sisse Helle Njor, Ilse Vejborg, and Elsebeth Lynge. 2005. "Do Nonattenders in Mammography Screening Programmes Seek Mammography Elsewhere?" *International Journal of Cancer* 113 (3): 464–470.
- Jeon, Sung-Hee, and R. Vincent Pohl. 2019. "Medical Innovation, Education, and Labor Market Outcomes of Cancer Patients." *Journal of Health Economics* 68:102228.
- Johnsson, Aina, Tommy Fornander, Lars-Erik Rutqvist, Marjan Vaez, Kristina Alexander, and Mariann Olsson. 2009. "Predictors of Return to Work Ten Months after Primary Breast Cancer Surgery." *Acta Oncologica* 48 (1): 93–98.
- Kalemli-Ozcan, Sebnem, and David N. Weil. 2010. "Mortality Change, the Uncertainty Effect, and Retirement." *Journal of Economic Growth* 15 (1): 65–91.
- Lee, David S., Justin McCrary, Marcelo J. Moreira, and Jack Porter. 2022. "Valid T-Ratio Inference for IV." *American Economic Review* 112 (10): 3260–3290.
- Lindbohm, M.-L., E. Kuosma, T. Taskila, P. Hietanen, K. Carlsen, S. Gudbergsson, and H. Gunnarsdottir. 2014. "Early Retirement and Non-Employment after Breast Cancer." *Psycho-Oncology* 23 (6): 634–641.
- Lynge, Elsebeth, Martin Bak, My von Euler-Chelpin, Niels Kroman, Anders Lernevall, Nikolaj Borg Mogensen, Walter Schwartz, Adam Jan Wronecki, and Ilse Vejborg. 2017. "Outcome of Breast Cancer Screening in Denmark." *BMC Cancer* 17.
- Mariotto, Angela B., Lindsey Enewold, Jingxuan Zhao, Christopher A. Zeruto, and K. Robin Yabroff. 2020. "Medical Care Costs Associated with Cancer Survivorship in the United States." *Cancer Epidemiology, Biomarkers & Prevention* 29 (7): 1304–1312.

- Minton, O., and P. Stone. 2008. "How Common Is Fatigue in Disease-Free Breast Cancer Survivors? A Systematic Review of the Literature." *Breast Cancer Research and Treatment* 112 (1): 5–13.
- Møller, Susanne, Maj-Britt Jensen, Bent Ejlertsen, Karsten D. Bjerre, Martin Larsen, Hanne B. Hansen, Peer Christiansen, and Henning T. Mouridsen. 2008. "The Clinical Database and the Treatment Guidelines of the Danish Breast Cancer Cooperative Group (DBCG); Its 30-Years Experience and Future Promise." *Acta Oncologica* 47 (4): 506–524.
- Mueller-Smith, Michael. 2015. "The Criminal and Labor Market Impacts of Incarceration."
- OECD. 2023. *Health at a Glance 2023*. Paris: OECD Publishing.
- Olsen, Kim Rose, Henriette Mabeck, Dorte Gyrd-Hansen, Marie Henriette Madsen, and Thyra Pallesen. 2007. "Status Og Sammenligning Af de 6 Danske Strålecentre." Dansk Sundhedsinstitut Hovedrapport.
- Overgaard, Marie, Per S. Hansen, Jens Overgaard, Carsten Rose, Michael Andersson, Flemming Bach, Mogens Kjaer, et al. 1997. "Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy." *New England Journal of Medicine* 337 (14): 949–955.
- Papageorge, Nicholas W. 2016. "Why Medical Innovation Is Valuable: Health, Human Capital, and the Labor Market." *Quantitative Economics* 7 (3): 671–725.
- Pedersen, Peder J., and Mona Larsen. 2008. "Pathways to Early Retirement in Denmark, 1984-2000." *International Journal of Manpower* 29 (5): 384–409.
- Pignol, Jean-Philippe, Pauline Truong, Eileen Rakovitch, Margriet G. Sattler, Timothy J. Whelan, and Ivo A. Olivotto. 2016. "Ten Years Results of the Canadian Breast Intensity Modulated Radiation Therapy (IMRT) Randomized Controlled Trial." *Radiotherapy and Oncology* 121 (3): 414–419.
- Ragaz, Joseph, Stewart M. Jackson, Nhu Le, Ian H. Plenderleith, John J. Spinelli, Vivian E. Basco, Kenneth S. Wilson, et al. 1997. "Adjuvant Radiotherapy and Chemotherapy in Node-Positive Premenopausal Women with Breast Cancer." *New England Journal of Medicine* 337 (14): 956–962.
- Rayan, Gamal, Laura A Dawson, Andrea Bezjak, Anthea Lau, Anthony W Fyles, Qi-Long Yi, Pat Merante, and Katherine A Vallis. 2003. "Prospective Comparison of Breast Pain in Patients Participating in a Randomized Trial of Breast-Conserving Surgery and Tamoxifen with or without Radiotherapy." *International Journal of Radiation Oncology\*Biology\*Physics* 55 (1): 154–161.

- Sanders, Gillian D., Peter J. Neumann, Anirban Basu, Dan W. Brock, David Feeny, Murray Krahn, Karen M. Kuntz, et al. 2016. "Recommendations for Conduct, Methodological Practices, and Reporting of Cost-Effectiveness Analyses: Second Panel on Cost-Effectiveness in Health and Medicine." *JAMA* 316 (10): 1093–1103.
- Schwiebert, Jörg. 2015. "Estimation and Interpretation of a Heckman Selection Model with Endogenous Covariates." *Empirical Economics* 49 (2): 675–703.
- St Germain, Diane, Andrea Denicoff, Andrea Torres, Joseph Kelaghan, Worta McCaskill-Stevens, Grace Mishkin, Ann O'Mara, and Lori M. Minasian. 2020. "Reporting of Health-Related Quality of Life Endpoints in National Cancer Institute-Supported Cancer Treatment Trials." *Cancer* 126 (11): 2687–2693.
- Stephens Jr., Melvin, and Desmond Toohey. 2022. "The Impact of Health on Labor Market Outcomes: Evidence from a Large-Scale Health Experiment." *American Economic Journal: Applied Economics* 14 (3): 367–399.
- Thirumurthy, Harsha, and Joshua Graff Zivin. 2012. "Health and Labor Supply in the Context of HIV/AIDS: The Long-Run Economic Impacts of Antiretroviral Therapy." *Economic Development and Cultural Change* 61 (1): 73–96.
- Thirumurthy, Harsha, Joshua Graff Zivin, and Markus Goldstein. 2008. "The Economic Impact of AIDS Treatment: Labor Supply in Western Kenya." *Journal of Human Resources* 43 (3): 511–552.
- Timbie, Justin W., Marcela Horvitz-Lennon, Richard G. Frank, and Sharon-Lise T. Normand. 2006. "A Meta-Analysis of Labor Supply Effects of Interventions for Major Depressive Disorder." *Psychiatric Services* 57 (2): 212–218.
- Velikova, Galina, Linda Jane Williams, Sarah Willis, J. Michael Dixon, Juliette Lancaster, Matthew Hatton, Jacqueline Clarke, et al. 2018. "Quality of Life after Postmastectomy Radiotherapy in Patients with Intermediate-Risk Breast Cancer (SUPREMO): 2-Year Follow-up Results of a Randomised Controlled Trial." *Lancet Oncology* 19 (11): 1516–1529.
- Weil, David N. 2007. "Accounting for the Effect Of Health on Economic Growth\*." *Quarterly Journal of Economics* 122 (3): 1265–1306.
- Whelan, Timothy J., Mark Levine, Jim Julian, Peter Kirkbride, Peter Skingley, and Ontario Clinical Oncology Group. 2000. "The Effects of Radiation Therapy on Quality of Life of Women with Breast Carcinoma." *Cancer* 88 (10): 2260–2266.
- Wilson, Michelle K, Katherine Karakasis, and Amit M Oza. 2015. "Outcomes and Endpoints in Trials of Cancer Treatment: The Past, Present, and Future." *Lancet Oncology* 16 (1): e32–e42.






Figure 1: Eligibility for Radiation Therapy, 1990–1998




*Notes:* This figure presents the regression-adjusted probability of receiving radiation therapy by year of diagnosis. We regress the indicator for receipt of radiation therapy on indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm). The regressions are estimated separately for T95 and the comparison group. Each dot plots the average of the residuals from these regressions for women diagnosed in the year indicated on the horizontal axis. The solid line represents the women in T95 while the dashed line represents the women in the comparison group.

Figure 2: The Effect of the 1995 Guideline Change on Radiation Therapy Take-Up




*Notes:* Each point and vertical segment represent the 2SLS estimate and its corresponding 95% confidence interval for the coefficient of the radiotherapy indicator from a different regression of the outcome indicated, measured at the time shown on the horizontal axis, on all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. The instrument is the interaction between an indicator for the woman belonging to the T95 group and an indicator for being diagnosed in or after 1995. Standard errors are clustered at the hospital level.

Figure 3: Effects of Radiation Therapy on Mortality, 2SLS Estimates




((a)) Employment Status



Notes: See the notes to Figure 3.

Figure 4: Effects of Radiation Therapy on Labor Market Outcomes, 2SLS Estimates



*Notes:* Each point represents the average of the outcome indicated in the panel, calculated among the group of women indicated in the legend and measured at the time indicated on the horizontal axis.

Figure 5: The Evolution of Outcomes in the T95 and Control Group by Year Since Diagnosis

Table 1: Sample Construction

	Observations
Diagnosed between 1990–1998:	26,900
— not in DBCG89	9,644
— post-menopausal	11,929
— low or unknown risk	1,646
— always eligible for whom dosage of radiotherapy changed	564
— missing values for key variables:	277
— age 55+ at the time of diagnosis:	17
Analysis sample	<u>2,823</u>

Table 2: Descriptive Statistics

	All	Treated with RT		<i>p</i> -value
	(1)	Yes (2)	No (3)	(4)
<b>A. Demographic Characteristics</b>				
Age at diagnosis	43.52 (5.64)	42.90 (5.91)	44.18 (5.25)	0.000
Years of education	12.87 (2.99)	13.04 (2.88)	12.70 (3.09)	0.003
Married?	0.70	0.66	0.73	0.000
Immigrant?	0.04	0.04	0.04	0.971
Characteristics 2-4 years pre-diagnosis				
Employed?	0.84	0.84	0.84	0.862
Unemployed?	0.06	0.06	0.06	0.862
Out of the labor force?	0.10	0.10	0.10	0.909
Labor earnings	220.39 (141.51)	224.90 (145.99)	215.58 (136.45)	0.080
Gross personal income	278.43 (122.64)	285.63 (125.86)	270.74 (118.67)	0.001
<b>B. Disease Pathology</b>				
Tumor size in mm	26.04	27.63	24.34	0.000
≤ 20mm?	0.49	0.46	0.52	0.000
21–50mm?	0.44	0.45	0.43	0.249
≥ 51mm?	0.07	0.10	0.05	0.000
Number of positive nodes	2.61	3.64	1.51	0.000
Zero?	0.39	0.30	0.50	0.000
1–3?	0.34	0.31	0.38	0.000
4+?	0.26	0.39	0.12	0.000
Carcinoma not removed micro-radically?	0.04	0.06	0.01	0.000
Had mastectomy?	0.82	0.69	0.96	0.000
Had lumpectomy?	0.15	0.29	0.01	0.000
Had lumpectomy followed by mastectomy?	0.03	0.03	0.03	0.859
<b>C. Health Outcomes</b>				
Died:				
5 years after diagnosis?	0.20	0.22	0.18	0.014
10 years after diagnosis?	0.32	0.35	0.30	0.006
Died of breast cancer:				
5 years after diagnosis?	0.19	0.21	0.17	0.005
10 years after diagnosis?	0.30	0.33	0.28	0.002

Table 2 (cont.): Descriptive Statistics

	All	Treated with RT		<i>p</i> -value
	(1)	Yes (2)	No (3)	
<b>D. Labor Market Outcomes</b>				
Employed:				
5 years after diagnosis?	0.56	0.55	0.57	0.340
10 years after diagnosis?	0.43	0.43	0.42	0.778
Unemployed:				
5 years after diagnosis?	0.02	0.02	0.02	0.872
10 years after diagnosis?	0.02	0.01	0.02	0.071
Out of the labor force:				
5 years after diagnosis?	0.42	0.42	0.41	0.311
10 years after diagnosis?	0.56	0.56	0.55	0.843
Labor earnings:				
5 years after diagnosis?	174.01 (174.39)	178.65 (178.07)	169.04 (170.28)	0.143
10 years after diagnosis?	147.85 (183.12)	151.73 (188.50)	143.70 (177.16)	0.243
Gross personal income:				
5 years after diagnosis?	233.37 (171.22)	235.10 (178.49)	231.52 (163.14)	0.578
10 years after diagnosis?	202.35 (185.06)	200.39 (189.80)	204.45 (179.89)	0.559
Any government transfer:				
1–5 years after diagnosis?	0.48	0.55	0.41	0.000
6–10 years after diagnosis?	0.35	0.38	0.33	0.006
Sickness benefits:				
1–5 years after diagnosis?	0.35	0.41	0.29	0.000
6–10 years after diagnosis?	0.24	0.25	0.23	0.323
Disability benefits:				
1–5 years after diagnosis?	0.16	0.19	0.13	0.000
6–10 years after diagnosis?	0.15	0.17	0.13	0.006
Number of observations	2,823	1,459	1,364	

Notes: Columns 1–3 list means and standard deviation (in parentheses) of the characteristics indicated in the row in the sample indicated in the column. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. Demographic characteristics are measured in the year of diagnosis or averaged over the period 2–4 years before diagnosis, as indicated. Column 4 presents *p*-values for the test of equality of the means between patients treated and not treated with radiotherapy.

Table 3: Effects of the 1995 Guideline Change on Adjuvant Radiation Therapy Take-Up in Different Subsamples

	Baseline	Years of education		Pre-diagnosis labor income	
		$\leq 12$	$> 12$	$\leq$ median	$>$ median
		(1)	(2)	(3)	(4)
$T95 \times Post95$	0.753*** (0.018)	0.751*** (0.035)	0.750*** (0.021)	0.731*** (0.031)	0.787*** (0.022)
Observations	2,823	1,022	1,729	1,407	1,407

	Baseline	Marital status		Predicted 10-year mortality	
		Single	Married	$\leq$ median	$>$ median
		(1)	(6)	(7)	(8)
$T95 \times Post95$	0.753*** (0.018)	0.766*** (0.034)	0.758*** (0.021)	0.825*** (0.025)	0.680*** (0.031)
Observations	2,823	860	1,963	1,400	1,398

*Notes:* OLS estimates based on the first-stage Equation (2). Each cell presents the estimate of the coefficient on the instrument ( $T95_t \times Post95_t$ ) from a separate regression estimated in the sample indicated in the column heading. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. Years of education and marital status are measured in the year of diagnosis. Pre-diagnosis labor income is the average of the yearly labor income earned over the period 2–4 years before diagnosis. Predicted 10-year breast cancer mortality is obtained by applying to our analysis sample the prediction from a probit regression of an indicator for dying from breast cancer during the ten years after diagnosis on indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. This regression is estimated in the sample of all the breast cancer patients diagnosed during our sample period who are not included in our analysis sample and who are not treated with radiation therapy. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

Table 4: Effects of Adjuvant Radiation Therapy on Government Transfers, 2SLS Estimates

	Years since diagnosis	
	1–5 (1)	6–10 (2)
Any government transfer?	-0.091** (0.037)	-0.097* (0.049)
Mean outcome	0.411	0.328
Sickness benefits?	-0.078** (0.039)	-0.085* (0.044)
Mean outcome	0.285	0.230
Disability pension?	-0.030 (0.033)	-0.049 (0.035)
Mean outcome	0.125	0.128
Number of weeks with any government transfer	-4.837 (6.424)	-9.225 (7.950)
Mean outcome	28.181	31.187
Number of weeks on sickness benefits	-3.463 (2.520)	-3.449* (2.041)
Mean outcome	8.443	9.558
Number of weeks on disability pension	-2.831 (6.195)	-5.554 (8.041)
Mean outcome	21.961	31.596

Notes: 2SLS estimates based on Equation (1), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the indicator for radiotherapy from a separate regression for the outcome indicated in the row aggregated over the period indicated in the column. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. The instrument is the interaction between an indicator for the woman belonging to the T95 group and an indicator for being diagnosed in or after 1995. Variable names ending in a question mark are dummy variables with one being yes and zero being no. The reported mean of the outcome is calculated among women who do not receive radiotherapy. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

# **Do Medical Treatments Work for Work? Evidence from Breast Cancer Patients**

## *Online Appendix*

N. Meltem Daysal

*University of Copenhagen, CEBI, CESifo, and IZA*

William N. Evans

*University of Notre Dame, NBER, and J-PAL*

Mikkel Hasse Pedersen

*EY Denmark*

Mircea Trandafir

*Rockwool Foundation Research Unit and IZA*

## A1 Additional Sources of Income Insurance Against Health Shocks

**Unemployment Insurance.** In Denmark, employers have the right to terminate the employment of workers who have been on sick leave for extended periods of time, typically a total of 120 days during a period of 12 months. Unlike other forms of social security, unemployment insurance is not automatic. Instead, individuals must apply to become members of an unemployment fund (A-kasse). During our study period around 78% of individuals were members of an A-kasse.

Members of an A-kasse are entitled to unemployment benefits if they are employed for at least 52 weeks during the previous 3 years. During our study period, members could receive benefits for a maximum period of 7 years (until 1993) or 5 years (after 1994). Benefit amounts were calculated as 90% of the earnings in the year before the job loss with a maximum weekly amount of DKK 2,615 (559 USD) in 1996.

**Social Assistance.** Benefits provided by the social assistance program are means-tested and also depend on age and marital status. During our study period, social assistance benefits typically amounted to 60 to 80% of the maximum level of unemployment benefits (Pedersen and Larsen, 2008). In contrast to unemployment benefits, individuals could receive social assistance benefits for an unlimited period of time.

**Early Retirement.** Individuals who are members of an unemployment insurance fund and have been so for a sufficiently long period of time are eligible for early retirement before the full retirement age. The full retirement age for individuals born before July 1, 1939 is 67. Individuals born after that date are eligible for retirement at age 65. Both groups are eligible for early retirement at age 60. Individuals transition into the old-age pension program at the full-retirement age. The early retirement pension was reformed several times during the course of our study. The benefit levels typically equaled 80-100% of the maximum unemployment insurance benefit level, depending on the age of entry into early retirement (Bingley et al., 2012).

## A2 Control Function Approach to Heckman Selection Model with Endogenous Covariates

The structural equation of interest is Equation (1):

$$Y_{it}^a = \alpha_1 + RT_{it}\beta_1 + \mathbf{X}_{it}\gamma_1 + u_{1t} + \epsilon_{1it}. \quad (1)$$

There are two fundamental problems with estimating Equation (1) via OLS. The first is what we focus on in the main text, which is that  $RT_{it}$  is potentially correlated with the error term  $\epsilon_{1it}$ . The second is that the actual values of  $Y_{it}^a$  are only observed for those that live until period  $t$ . The first problem is handled as before with the first-stage Equation (2):

$$RT_{it} = \alpha_2 + T95_i Post95_t\beta_2 + \mathbf{X}_{it}\gamma_2 + u_{2t} + \epsilon_{2it}. \quad (2)$$

The second problem is characterized by a third equation that identifies selection into the sample in period  $t$ . Let  $s_{it}^*$  be an index that identifies the propensity for a person to survive until period  $a$  and the person will survive if  $s_{it}^* > 0$ . The observed economic outcome is therefore  $Y_{it}^a | s_{it}^* > 0$ . The survival index is driven by the underlying

equation:


$$s_{it}^* = \alpha_4 + R T_{it} \beta_4 + \mathbf{Z}_{it} \theta_4 + \mathbf{X}_{it} \gamma_4 + \epsilon_{4it}, \quad (\text{A2.1})$$

where the vector  $\mathbf{Z}_{it}$  contains factors that impact survivability but not labor supply ( $\epsilon_{1it}$ ). Let  $s_{it} = 1$  which only occurs if  $s_{it}^* > 0$ . When the error terms are jointly normally distributed, this is a Heckman (1974) selection model with endogenous covariates in the outcome equation of interest. Schwiebert (2015) outlines a control-function approach to estimation. Equation (2) is first estimated by OLS and the residuals from that regression are then added to Equation (1) and, assuming the errors terms  $\epsilon_{1it}$  and  $\epsilon_{4it}$  are bivariate normally distributed, Equation (1) and Equation (A2.1) are estimated via FIML. The model requires that we include one or more excluded instruments in the selection equation (A2.1), i.e., variables that plausibly affect survivability but have no direct effect on labor market outcomes. The excluded instruments are triple interactions between the T95 indicator, an indicator for being diagnosed after 1995, and (i) an indicator for having a tumor larger than 5cm, or (ii) indicators for the type of surgery (i.e., breast conserving or mastectomy). These variables strongly predict mortality but should not necessarily be predictive of labor supply. We make one further change to our specification to reduce the computational burden: we reduce the dimensionality of the covariates in Equations (1), (2) and (A2.1) by replacing the full set of interactions between the indicators for clinical characteristics determining RT eligibility with the T95 indicator, and the set of year-of-diagnosis fixed effects with an indicator for diagnosis in or after 1995. Column 3 in Appendix Table A9 below shows that this change leaves our baseline results (reported in Column 1) virtually unchanged.


Definitions	Trial arm	Adjuvant treatment	Start	End
Age eligibility: < 75 years	A Low risk High risk: • Receptor status positive, 70-74 years	None		
<u>Low risk:</u> Tumor ≤ 5cm and positive nodes and grade I (if premenopausal)	B High risk: • Premenopausal, receptor status positive, positive nodes	1 CMF 2 OA	Jan. 90	Jun. 98
<u>High risk:</u> Tumor > 5 cm or Positive nodes or (Premenopausal and ductal grade II-III)	C High risk: • Postmenopausal, receptor status positive/unknown	1 Tamoxifen 1 year 2 Tamoxifen 2 years 3 Tamoxifen ½ year + Megace ½ year Tamoxifen 5 years	Jan. 90	Jan. 97
<u>Radiation therapy:</u> • Lumpectomy • Carcinoma not removed microradically • Additional eligibility criteria: – Age ≤ 45 years and ≥ 4 positive nodes (until Jan. 95) – Premenopausal, positive nodes or tumor > 5 cm (from Jan. 95)	D High risk: • Premenopausal, positive nodes or receptor status positive/unknown • Postmenopausal, receptor status positive, < 70 years	1 CMF 2 CEF 3 CMF + pamidronate 4 CEF + pamidronate	Dec. 89	Jun. 98

*Notes:* Summary of the DBCG89 randomized control trial protocol, based on the [official protocol](#) provided by the Danish Breast Cancer Cooperative Group, last accessed on December 20, 2024. “Positive nodes” indicates that the cancer spread to at least one lymph node. “Receptor status” refers to the presence of hormone receptors. “CMF” stands for the cyclophosphamide, methotrexate, and fluorouracil treatment regimen, while the “CEF” regimen substitutes epirubicin for methotrexate. Finally, OA indicates ovarian ablation (the removal of ovaries).

Appendix Figure A1: DBCG89 Randomized Control Trial Protocol




((a)) Yearly Raw Data




((b)) Quarterly Regression-Adjusted Data

Notes: Panel (a) plots the fraction of breast cancer patients receiving radiotherapy by year of diagnosis, separately for T95 and the comparison group. Panel (b) presents the regression-adjusted probability of receiving radiation therapy by year and quarter of diagnosis. The regression-adjusted probability of receiving radiation therapy is the residual from a regression of the indicator for receipt of radiation therapy on indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm). The regressions are estimated separately for T95 and the comparison group. Each dot in Panel (b) represents the average of the residuals from these regressions for women diagnosed in the year and quarter indicated on the horizontal axis.


Appendix Figure A2: The Effect of the 1995 Guideline Change on Radiation Therapy Take-Up



((a)) Mortality




((b)) Employment Status




((c)) Income

*Notes:* Each point and vertical segment represents the 2SLS estimate of Equation (1) using the full set of control variables described in the notes to Appendix Table A4 and its corresponding 95% confidence interval for the coefficient of the radiotherapy indicator. We estimate separate 2SLS regressions for each outcome measured at the time shown on the horizontal axis.


Appendix Figure A3: Placebo Effects of Radiation Therapy Guideline Change Among the Control Group




((a)) Died of any cause



((b)) Died of breast cancer




((c)) Employed




((d)) Unemployed


Appendix Figure A4: Robustness of Results, Average Outcomes 1–5 Years After Diagnosis




((e)) Out of the labor force



((f)) Labor income




((g)) Total income




((h)) Any welfare

Appendix Figure A4 (cont.): Robustness of Results, Average Outcomes 1–5 Years After Diagnosis




*Notes:* Each point and line segment represent the 2SLS estimate of Equation (1) using the full set of control variables described in the notes to Appendix Table A4 and its corresponding 95% confidence interval for the coefficient of the radiotherapy indicator. We estimate separate 2SLS regressions for each outcome, averaged over the period 1–5 years after diagnosis (labor market outcomes) or cumulatively 5 years after diagnosis (mortality, use of government transfers). “Baseline” represents our baseline specification, Equation (1). “Sociodemographic controls,” “Hospital fixed effects,” and “Pre-diagnosis outcomes” indicate specifications that add to Equation (1) the demographic characteristics listed in Table 2, fixed effects for the treatment hospital, or the average of the corresponding outcome over the period 2–4 years before diagnosis, respectively. “Excluding 1994,” “Excluding screening areas” and “Excluding lumpectomies” indicate that the estimation sample does not include women diagnosed in 1994, women residing in areas with pilot universal screening programs, or women undergoing breast-conserving surgeries, respectively. Finally, “always eligible” and “never eligible” indicate that the control group only includes women who were eligible or not eligible for radiotherapy regardless of the year of diagnosis, respectively.


Appendix Figure A4 (cont.): Robustness of Results, Average Outcomes 1–5 Years After Diagnosis




((a)) Died of any cause



((b)) Died of breast cancer




((c)) Employed




((d)) Unemployed


Appendix Figure A5: Robustness of Results, Average Outcomes 6–10 Years After Diagnosis




((e)) Out of the labor force



((f)) Labor income




((g)) Total income




((h)) Any welfare

Appendix Figure A5 (cont.): Robustness of Results, Average Outcomes 6–10 Years After Diagnosis




*Notes:* Each point and line segment represent the 2SLS estimate of Equation (1) using the full set of control variables described in the notes to Appendix Table A4 and its corresponding 95% confidence interval for the coefficient of the radiotherapy indicator. We estimate separate 2SLS regressions for each outcome, averaged over the period 6–10 years after diagnosis (labor market outcomes) or cumulatively 5 years after diagnosis (mortality, use of government transfers). “Baseline” represents our baseline specification, Equation (1). “Sociodemographic controls,” “Hospital fixed effects,” and “Pre-diagnosis outcomes” indicate specifications that add to Equation (1) the demographic characteristics listed in Table 2, fixed effects for the treatment hospital, or the average of the corresponding outcome over the period 2–4 years before diagnosis, respectively. “Excluding 1994,” “Excluding screening areas” and “Excluding lumpectomies” indicate that the estimation sample does not include women diagnosed in 1994, women residing in areas with pilot universal screening programs, or women undergoing breast-conserving surgeries, respectively. Finally, “always eligible” and “never eligible” indicate that the control group only includes women who were eligible or not eligible for radiotherapy regardless of the year of diagnosis, respectively.


Appendix Figure A5 (cont.): Robustness of Results, Average Outcomes 6–10 Years After Diagnosis




((a)) Employed 5 Years After Diagnosis



((b)) Employed 10 Years After Diagnosis




((c)) Labor Earnings 5 Years After Diagnosis



((d)) Labor Earnings 10 Years After Diagnosis


*Notes:* Each point represents the average of the 2SLS estimate and the corresponding empirical 95% confidence interval for the coefficient of the radiotherapy indicator from 100 replications of the baseline model, using the full set of control variables described in the notes to Appendix Table A4, after replacing the outcomes of a random sample of non-survivors among T95 in the pre-1995 period with the employment rate indicated in the horizontal axis (panels a and b) or with the percentile of labor earnings among survivors in T95 in the post-1995 period indicated in the horizontal axis (panels c and d). The number of selected non-survivors corresponds to the estimated mortality gain at that time after diagnosis. The vertical dotted line indicates the average employment rate (panels a and b) the median labor earnings (panels c and d) among survivors in T95 in the post-1995 period. The horizontal solid red line indicates the baseline 2SLS estimate.

Appendix Figure A6: The Role of Mortality in Driving the Results, Employment and Labor Earnings



*Notes:* Each point and vertical segment represent the 2SLS estimate of Equation (1) using the full set of control variables described in the notes to Appendix Table A4 and its corresponding 95% confidence interval for the coefficient of the radiotherapy indicator. We estimate separate 2SLS regressions for each outcome measured at the time shown on the horizontal axis.

Appendix Figure A7: Effect of Radiation Therapy on Employment, Exit from Labor Force, and Yearly Recurrence



*Notes:* Each point and vertical segment represent the 2SLS estimate of Equation (1) using the full set of control variables described in the notes to Appendix Table A4 and its corresponding 95% confidence interval for the coefficient of the radiotherapy indicator. We estimate separate 2SLS regressions for the cumulative number of inpatient and outpatient hospital contacts from diagnosis until each time shown on the horizontal axis.

Appendix Figure A8: Effects of Radiation Therapy on Hospitalizations

Appendix Table A1: Descriptive Statistics for Women Diagnosed Before and After the RT Guideline Change

	Treated with RT		Not treated with RT	
	Before 1995 (1)	After 1995 (2)	Before 1995 (3)	After 1995 (4)
<b>A. Demographic Characteristics</b>				
Age at diagnosis	41.60 (5.86)	43.63 (5.81)	44.38 (5.14)	43.67 (5.52)
Years of education	12.89 (3.06)	13.12 (2.77)	12.52 (3.11)	13.17 (2.99)
Married?	0.68	0.66	0.73	0.72
Immigrant?	0.05	0.03	0.03	0.07
Characteristics 2–4 years pre-diagnosis				
Employed?	0.85	0.83	0.84	0.82
Unemployed?	0.07	0.05	0.06	0.06
Out of the labor force?	0.08	0.12	0.09	0.12
Labor earnings (thousands)	217.63 (136.01)	228.98 (151.23)	211.27 (132.57)	226.71 (145.60)
Gross personal income (thousands)	269.77 (113.59)	294.53 (131.47)	263.03 (116.21)	290.65 (122.73)
<b>B. Disease Pathology</b>				
Tumor size in mm	29.94	26.34	25.38	21.66
≤ 20mm?	0.41	0.48	0.51	0.56
21–50mm?	0.46	0.44	0.43	0.41
≥ 51mm?	0.12	0.08	0.06	0.03
Number of positive nodes	4.10	3.39	1.93	0.41
Zero?	0.40	0.24	0.36	0.86
1–3?	0.10	0.43	0.49	0.09
4+?	0.50	0.33	0.15	0.05
Carcinoma not removed micro-radically?	0.11	0.04	0.01	0.00
Had mastectomy?	0.60	0.73	0.97	0.93
Had lumpectomy?	0.39	0.23	0.01	0.02
Had lumpectomy followed by mastectomy?	0.02	0.03	0.02	0.05
<b>C. Health Outcomes</b>				
Died:				
5 years after diagnosis?	0.25	0.20	0.20	0.14
10 years after diagnosis?	0.39	0.32	0.33	0.22
Died of breast cancer:				
5 years after diagnosis?	0.25	0.19	0.19	0.14
10 years after diagnosis?	0.38	0.30	0.30	0.20

*Notes:* Means and standard deviation (in parentheses) of the characteristics indicated in the row in the sample indicated in the column. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. Demographic characteristics are measured in the year of diagnosis or averaged over the period 2–4 years before diagnosis, as indicated.

Appendix Table A1 (cont.): Descriptive Statistics for Women Diagnosed Before and After the RT Guideline Change

	Treated with RT		Not treated with RT	
	Before 1995 (1)	After 1995 (2)	Before 1995 (3)	After 1995 (4)
<b>D. Labor Market Outcomes</b>				
Employed:				
5 years after diagnosis?	0.51	0.57	0.54	0.65
10 years after diagnosis?	0.41	0.44	0.39	0.50
Unemployed:				
5 years after diagnosis?	0.02	0.03	0.03	0.01
10 years after diagnosis?	0.02	0.01	0.03	0.01
Out of the labor force:				
5 years after diagnosis?	0.47	0.40	0.43	0.34
10 years after diagnosis?	0.57	0.55	0.58	0.49
Labor earnings:				
5 years after diagnosis?	157.34 (172.24)	190.60 (180.25)	155.56 (164.69)	203.81 (179.53)
10 years after diagnosis?	141.19 (180.49)	157.64 (192.69)	129.58 (168.72)	180.13 (192.77)
Gross personal income:				
5 years after diagnosis?	211.27 (164.72)	248.46 (184.50)	218.15 (159.21)	266.01 (168.24)
10 years after diagnosis?	182.77 (191.89)	210.26 (188.00)	188.07 (173.60)	246.71 (188.97)
Any government transfer:				
1–5 years after diagnosis?	0.26	0.30	0.29	0.29
6–10 years after diagnosis?	0.18	0.23	0.25	0.25
Sickness benefits:				
1–5 years after diagnosis?	0.10	0.16	0.14	0.17
6–10 years after diagnosis?	0.07	0.09	0.10	0.11
Disability benefits:				
1–5 years after diagnosis?	0.14	0.14	0.12	0.12
6–10 years after diagnosis?	0.10	0.14	0.14	0.14
Number of Observations	524	935	983	381

Notes: Means and standard deviation (in parentheses) of the characteristics indicated in the row in the sample indicated in the column. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. Demographic characteristics are measured in the year of diagnosis or averaged over the period 2–4 years before diagnosis, as indicated.

Appendix Table A2: Effects of Adjuvant Radiation Therapy on Mortality and Labor Market Outcomes, OLS Estimates

	Years since diagnosis									
	1 (1)	2 (2)	3 (3)	4 (4)	5 (5)	6 (6)	7 (7)	8 (8)	9 (9)	10 (10)
Died?	0.009 (0.008)	0.007 (0.014)	-0.018 (0.017)	-0.028 (0.022)	-0.056** (0.024)	-0.057** (0.024)	-0.061** (0.024)	-0.066*** (0.022)	-0.071*** (0.023)	-0.068*** (0.022)
Mean outcome	0.005	0.037	0.091	0.142	0.182	0.210	0.235	0.262	0.278	0.298
Died of breast cancer?	0.009 (0.008)	0.009 (0.014)	-0.011 (0.017)	-0.022 (0.022)	-0.049** (0.024)	-0.049* (0.025)	-0.055** (0.025)	-0.062*** (0.023)	-0.068*** (0.023)	-0.069*** (0.023)
Mean outcome	0.005	0.033	0.084	0.132	0.172	0.196	0.220	0.243	0.258	0.276
Employed?	0.004 (0.027)	0.015 (0.029)	0.051* (0.028)	0.050 (0.031)	0.033 (0.026)	0.029 (0.031)	0.025 (0.032)	0.047 (0.028)	0.052* (0.028)	0.046 (0.029)
Mean outcome	0.729	0.683	0.625	0.590	0.569	0.540	0.521	0.496	0.456	0.424
Unemployed?	0.008 (0.012)	-0.010 (0.012)	-0.002 (0.012)	0.015 (0.010)	0.009 (0.008)	0.020*** (0.009)	0.025** (0.012)	0.014 (0.009)	-0.001 (0.006)	0.010 (0.007)
Mean outcome	0.054	0.047	0.040	0.032	0.025	0.028	0.017	0.022	0.025	0.022
Out of labor force?	-0.031 (0.020)	-0.005 (0.026)	-0.049* (0.027)	-0.065** (0.031)	-0.042* (0.025)	-0.049* (0.029)	-0.051* (0.029)	-0.060** (0.027)	-0.051* (0.027)	-0.056** (0.027)
Mean outcome	0.152	0.271	0.336	0.378	0.406	0.433	0.463	0.482	0.519	0.554
Annual labor income	9.961 (9.617)	3.717 (9.983)	11.060 (11.045)	16.142 (9.914)	15.272 (10.659)	13.485 (11.034)	13.581 (11.935)	11.997 (11.961)	16.878 (10.981)	19.892* (10.973)
Mean outcome	207.445	199.525	188.281	176.824	168.533	162.338	158.934	154.349	150.507	143.179
Annual gross income	6.488 (8.632)	6.502 (9.306)	8.990 (10.029)	19.274* (10.951)	18.227 (11.069)	19.770 (11.956)	17.100 (12.226)	16.422 (11.314)	15.396 (12.685)	17.900 (11.806)
Mean outcome	275.107	263.301	252.104	237.931	230.073	220.608	217.998	212.011	211.982	203.078

*Note:* OLS estimates based on Equation (1), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the indicator for radiotherapy from a separate regression for the outcome indicated in the row measured at the time indicated in the column. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among women who do not receive radiotherapy. Standard errors are clustered at the hospital level. Significance levels: \* p<0.1 \*\* p<0.05 \*\*\* p<0.01.

Appendix Table A3: Effects of Adjuvant Radiation Therapy on Government Transfers, OLS Estimates

	Years since diagnosis	
	1–5 (1)	6–10 (2)
Any government transfer?	−0.032 (0.023)	−0.031 (0.026)
Mean outcome	0.411	0.328
Sickness benefits?	−0.031 (0.026)	−0.046* (0.025)
Mean outcome	0.285	0.230
Disability pension?	−0.007 (0.016)	−0.001 (0.020)
Mean outcome	0.125	0.128
Number of weeks with any government transfer	0.191 (3.495)	1.135 (4.383)
Mean outcome	28.181	31.187
Number of weeks on sickness benefits	2.553 (3.666)	4.558 (5.244)
Mean outcome	21.961	31.596
Number of weeks on disability pension	−0.031 (0.026)	−0.046* (0.025)
Mean outcome	0.285	0.230

*Notes:* OLS estimates based on Equation (1), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the indicator for radiotherapy from a separate regression for the outcome indicated in the row measured at the time indicated in the column. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among women who do not receive radiotherapy. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

Appendix Table A4: Effects of Adjuvant Radiation Therapy on Mortality and Labor Market Outcomes, 2SLS Estimates

	Years since diagnosis									
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)
	1	2	3	4	5	6	7	8	9	10
Died?	0.002 (0.011)	0.001 (0.020)	-0.046 (0.035)	-0.054 (0.042)	-0.107** (0.046)	-0.098** (0.049)	-0.108** (0.046)	-0.102** (0.050)	-0.103** (0.047)	
Mean outcome	0.005 0.037	0.091 0.037	0.142 0.142	0.182 0.182	0.210 0.235	0.235 0.262	0.235 0.278	0.235 0.278	0.235 0.298	
Died of breast cancer?	0.002 (0.011)	-0.002 (0.019)	-0.039 (0.035)	-0.049 (0.041)	-0.097** (0.045)	-0.087** (0.047)	-0.095** (0.048)	-0.109** (0.044)	-0.104** (0.049)	-0.109** (0.047)
Mean outcome	0.005 0.033	0.084 0.132	0.132 0.172	0.172 0.196	0.220 0.220	0.220 0.243	0.220 0.243	0.220 0.258	0.220 0.258	0.220 0.276
Employed?	0.086** (0.039)	0.099** (0.049)	0.157*** (0.052)	0.161*** (0.050)	0.155*** (0.058)	0.142** (0.067)	0.129* (0.067)	0.144** (0.062)	0.173*** (0.060)	0.155*** (0.057)
Mean outcome	0.796 0.683	0.683 0.625	0.625 0.590	0.590 0.569	0.540 0.540	0.521 0.521	0.496 0.496	0.496 0.456	0.496 0.424	
Unemployed?	-0.018 (0.022)	-0.030 (0.019)	-0.032** (0.016)	0.018 (0.015)	0.002 (0.017)	0.012 (0.014)	0.021* (0.012)	0.025* (0.013)	0.000 (0.011)	0.007 (0.013)
Mean outcome	0.052 0.047	0.047 0.040	0.040 0.032	0.032 0.025	0.028 0.028	0.017 0.017	0.022 0.022	0.022 0.025		0.022
Out of labor force?	-0.068* (0.037)	-0.069 (0.043)	-0.125*** (0.047)	-0.178*** (0.058)	-0.157*** (0.055)	-0.154** (0.060)	-0.150** (0.061)	-0.168*** (0.062)	-0.174*** (0.059)	-0.162*** (0.055)
Mean outcome	0.152 0.271	0.152 0.271	0.336 0.336	0.378 0.378	0.406 0.406	0.433 0.433	0.463 0.463	0.482 0.482	0.519 0.519	0.554 0.554
Annual labor income	32.328* (18.103)	25.864 (16.875)	50.832*** (18.949)	53.255*** (18.662)	61.506** (23.274)	54.875** (22.859)	57.395** (23.368)	52.117** (25.008)	54.663** (25.263)	65.107** (24.749)
Mean outcome	207.445 263.301	199.525 252.104	188.281 237.931	176.824 230.073	168.533 220.608	162.338 217.998	158.934 212.011	154.349 211.982	150.507 203.078	143.179 203.078
Annual gross income	23.458 (19.667)	18.745 (18.696)	37.963* (20.926)	51.629** (22.192)	62.744** (24.981)	59.074** (27.445)	41.302 (26.050)	51.139** (24.718)	39.289 (29.628)	46.874* (27.154)
Mean outcome	275.107 263.301	263.301 252.104	252.104 237.931	237.931 230.073	230.073 220.608	220.608 217.998	220.608 212.011	220.608 211.982	220.608 211.982	220.608 203.078

*Notes:* 2SLS estimates based on Equation (1), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the indicator for radiotherapy from a separate regression for the outcome indicated in the row measured at the time indicated in the column. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBC G89 clinical trial arm); and year-of-diagnosis fixed effects. The instrument is the interaction between an indicator for the woman belonging to the T95 group and an indicator for being diagnosed in or after 1995. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among women who do not receive radiotherapy. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

Appendix Table A5: Effects of the 1995 Guideline Change on Mortality and Labor Market Outcomes, Reduced-Form Estimates

	Years since diagnosis										
	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	
	1	2	3	4	5	6	7	8	9	10	
Died?	0.002 (0.008)	0.000 (0.015)	-0.034 (0.027)	-0.041 (0.031)	-0.080** (0.035)	-0.073** (0.037)	-0.074** (0.037)	-0.081** (0.035)	-0.077** (0.038)	-0.077** (0.036)	
Mean outcome	0.005 0.037	0.091	0.142	0.182	0.210	0.235	0.262	0.278	0.278	0.298	
Died of breast cancer?	0.002 (0.008)	-0.001 (0.015)	-0.029 (0.027)	-0.037 (0.031)	-0.073** (0.034)	-0.065* (0.036)	-0.072** (0.036)	-0.082** (0.034)	-0.078** (0.038)	-0.082** (0.036)	
Mean outcome	0.005 0.033	0.084	0.132	0.172	0.196	0.220	0.243	0.258	0.258	0.276	
Employed?	0.063*** (0.030)	0.075** (0.037)	0.118*** (0.037)	0.121*** (0.039)	0.117*** (0.038)	0.107*** (0.043)	0.097* (0.050)	0.108** (0.046)	0.131*** (0.046)	0.117*** (0.043)	
Mean outcome	0.729 0.683	0.625	0.590	0.569	0.540	0.521	0.496	0.456	0.456	0.424	
Unemployed?	-0.018 (0.016)	-0.022 (0.015)	-0.024** (0.012)	0.013 (0.012)	0.001 (0.013)	0.009 (0.010)	0.016* (0.009)	0.019** (0.009)	0.000 (0.008)	0.005 (0.010)	
Mean outcome	0.054 0.047	0.040	0.032	0.032	0.025	0.028	0.017	0.022	0.025	0.022	
Out of labor force?	-0.045 (0.030)	-0.052 (0.032)	-0.094*** (0.035)	-0.134*** (0.043)	-0.118*** (0.042)	-0.116** (0.045)	-0.113*** (0.046)	-0.127*** (0.046)	-0.131*** (0.044)	-0.122*** (0.041)	
Mean outcome	0.152 0.271	0.336	0.378	0.406	0.433	0.463	0.482	0.519	0.554		
Annual labor income	24.334* (13.603)	19.469 (12.681)	38.263*** (14.260)	40.086*** (13.986)	46.298*** (17.515)	41.306*** (17.262)	43.203*** (17.646)	39.230*** (18.861)	41.146** (19.037)	49.008*** (18.729)	
Mean outcome	207.445 275.107	199.525 263.301	188.281 252.104	176.824 237.931	168.533 230.073	162.338 220.608	158.934 217.998	154.349 212.011	150.507 211.982	143.179 203.078	

*Notes:* OLS estimates of the reduced-form in Equation (3), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the instrument ( $T95_i Post95_t$ ) from a separate regression for the outcome indicated in the row measured at the time indicated in the column. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. The instrument is the interaction between an indicator for the woman belonging to the  $T95$  group and an indicator for being diagnosed in or after 1995. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among the control group (always and never eligible women) diagnosed in the period 1990–1994, before the change in guidelines. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

Appendix Table A6: Effects of the 1995 Guideline Change on Government Transfers, Reduced-Form Estimates

	Years since diagnosis	
	1–5 (1)	6–10 (2)
Any government transfer?	−0.068** (0.028)	−0.073** (0.037)
Mean outcome	0.411	0.328
Sickness benefits?	−0.059** (0.029)	−0.064* (0.033)
Mean outcome	0.285	0.230
Disability pension?	−0.023 (0.025)	−0.037 (0.026)
Mean outcome	0.125	0.128
Number of weeks with any government transfer	−3.641 (4.810)	−6.944 (5.938)
Mean outcome	28.181	31.187
Number of weeks on sickness benefits	−2.607 (1.901)	−2.596* (1.525)
Mean outcome	8.443	9.558
Number of weeks on disability pension	−2.131 (4.653)	−4.181 (6.044)
Mean outcome	21.961	31.596

*Notes:* OLS estimates of the reduced-form in Equation (3), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the instrument ( $T95_i Post95_t$ ) from a separate regression for the outcome indicated in the row measured at the time indicated in the column. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. The instrument is the interaction between an indicator for the woman belonging to the  $T95$  group and an indicator for being diagnosed in or after 1995. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among the control group (always and never eligible women) diagnosed in the period 1990–1994, before the change in guidelines. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

Appendix Table A7: Descriptive Statistics, *T*95 versus Comparison Patients Diagnosed During 1990–1994

	T95 (1)	Control group (2)	<i>p</i> -value (3)
<b>A. Disease Pathology</b>			
Tumor size in mm	28.86 (19.35)	25.30 (16.62)	0.000
≤ 20mm?	0.45	0.50	0.034
21–50mm?	0.45	0.44	0.810
≥ 51mm?	0.11	0.06	0.001
Number of positive nodes	2.94 (3.22)	2.46 (4.12)	0.010
Zero?	0.02	0.67	0.000
1–3?	0.76	0.00	0.000
4+?	0.22	0.33	0.000
Carcinoma not removed micro-radically?	0.00	0.09	0.000
Had mastectomy?	0.98	0.72	0.000
Had lumpectomy?	0.00	0.26	0.000
Had lumpectomy followed by mastectomy?	0.02	0.02	0.587
<b>B. Demographic Characteristics</b>			
Age at diagnosis	45.04 (5.24)	41.99 (5.44)	0.000
Years of education	12.49 (3.15)	12.79 (3.04)	0.062
Married?	0.71	0.71	0.910
Immigrant?	0.03	0.04	0.422
Characteristics 2–4 years pre-diagnosis			
Employed?	0.83	0.86	0.063
Unemployed?	0.07	0.05	0.046
Out of the labor force?	0.10	0.08	0.375
Labor earnings	208.92 (133.18)	217.47 (134.24)	0.216
Gross personal income	262.15 (115.98)	268.20 (114.72)	0.311
Number of Observations	703	804	

*Notes:* Columns 1 and 2 present the mean and standard deviation (in parentheses) of the characteristic indicated in the row in the sample indicated in the column among women diagnosed between 1990–1994. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. Demographic characteristics are measured in the year of diagnosis or averaged over the period 2–4 years before diagnosis, as indicated. Column 3 presents *p*-values for the test of equality of the means in Columns 1 and 2.

Appendix Table A8: Effects of Radiation Therapy on Predetermined Patient Characteristics

	(1)
Years of education	0.167 (0.286)
Mean outcome	12.698
Married?	-0.049 (0.044)
Mean outcome	0.729
Immigrant?	-0.010 (0.023)
Mean outcome	0.038
Observations	2,823

*Notes:* 2SLS estimates based on Equation (1), estimated in the full analysis sample ( $N = 2,823$ ). Each cell presents the estimate of the coefficient on the indicator for radiotherapy from a separate regression for the outcome indicated in the row measured in the year of diagnosis. All specifications include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically; separate indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm); and year-of-diagnosis fixed effects. The instrument is the interaction between an indicator for the woman belonging to the T95 group and an indicator for being diagnosed in or after 1995. Variable names ending in a question mark are dummy variables with one being yes and zero being no, while variables with monetary values are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among women who do not receive radiotherapy. Standard errors are clustered at the hospital level. Significance levels: \*  $p < 0.1$  \*\*  $p < 0.05$  \*\*\*  $p < 0.01$ .

Appendix Table A9: Sensitivity of Effects of Radiation Therapy to Selective Survival

	Baseline (1)	Only survivors (2)	Baseline with T95 and Post95 indicators (3)	Heckman selection model (4)
<b>A. Employed?</b>				
5 years after diagnosis	0.155*** (0.049)	0.120** (0.051)	0.153*** (0.049)	0.110** (0.054)
Observations	2,823	2,256	2,823	2,823
Mean outcome	0.560	0.701	0.560	0.560
F-statistic	1,375	1,154	1,142	
10 years after diagnosis	0.155*** (0.048)	0.159*** (0.057)	0.156*** (0.048)	0.153*** (0.059)
Observations	2,823	1,912	2,823	2,823
Mean outcome	0.427	0.631	0.428	0.427
F-statistic	1,375	905	1,142	
<b>B. Labor earnings</b>				
5 years after diagnosis	60.518*** (17.282)	52.336*** (18.925)	59.999*** (17.287)	50.017** (22.818)
Observations	2,823	2,256	2,823	2,823
Mean outcome	174.115	216.910	174.171	174.008
F-statistic	1,375	1,154	1,142	
10 years after diagnosis	63.973*** (17.969)	76.797*** (22.397)	64.102*** (17.983)	71.605*** (23.192)
Observations	2,823	1,912	2,823	2,823
Mean outcome	147.908	217.793	147.966	147.851
F-statistic	1,375	905	1,142	

*Notes:* Columns 1–3 present 2SLS estimates based on Equation (1), estimated in the full analysis sample (Columns 1 and 3) or in the sample of survivors only (Column 2). Column 4 shows the estimates from a Heckman selection model with endogenous covariates, estimated in the full analysis sample (see Appendix Section A2 for details). Each cell presents the estimate of the coefficient on the indicator for radiotherapy from a separate regression for the outcome indicated in the panel measured at the time indicated in the row. All the specifications include indicators for age at diagnosis in full years, tumor size in cm, the number of positive nodes (0, 1–3, 4+), having the tumor removed micro-radically, the type of surgery (lumpectomy, mastectomy, or lumpectomy followed by mastectomy), and the type of chemotherapy received (DBCG89 clinical trial arm). In addition, the specifications in Columns 1 and 2 include all possible interactions among the following indicators: having mastectomy, being younger than 45 years of age at diagnosis, the number of positive nodes (0, 1–3, 4+), having a tumor larger than 50mm, and having the tumor removed micro-radically, as well as year-of-diagnosis fixed effects; while the specifications in Columns 3 and 4 include indicators for the T95 group and for diagnosis in or after 1995. The instrument for the radiotherapy indicator is the interaction between an indicator for the woman belonging to the T95 group and an indicator for being diagnosed after 1995. The excluded instruments in the selection equation in Column 4 are triple interactions between the T95 indicator, an indicator for being diagnosed after 1995, and (i) an indicator for having a tumor larger than 5cm, or (ii) indicators for the type of surgery (i.e., breast conserving or mastectomy). “Employed?” is a dummy variable with one being yes and zero being no. “Labor earnings” are expressed in thousands of 2015 DKK. The reported mean of the outcome is calculated among women who do not receive radiotherapy. F-statistic is the robust first-stage F statistic for the test of significance of the instrument. Standard errors are clustered at the hospital level. Significance levels: \* p<0.1 \*\* p<0.05 \*\*\* p<0.01.